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Introduction 
There can be few diseases that have attracted so much attention in the public arena as asthma and 
attendant allergies. At one time, this disorder was considered to be due to spasmodic bronchospasm, 
and treatment was targeted accordingly, i.e. with extensive use of bronchodilators. 
Our views on asthma have changed radically over the last decade, accelerated by the ability to study 
cells and mediators directly via the fibre-optic bronchoscope. Like other chronic acquired disorders, 
such as rheumatoid arthritis and inflammatory bowel disease, asthma is a chronic inflammatory 
disorder. The cellular constituents involving mast cells and eosinophils are typical of allergic disorders. 
Molecular technology has allowed a myriad of mediators to be identified as contributing both to the 
acute and chronic aspects of the disease, resulting in airways that contract too much and too early. 
Major inroads have been made into the immunological mechanism driving the inflammatory 
response with T-cells taking primacy, and B-cells (via IgE) providing a trigger stimulus involving 
common allergens. Sensitization of the respiratory tract to common allergens, particularly those of the 
domestic environment, is the first step and involves not only allergen recognition but also inhibition of 
mechanisms that normally prevent sensitization. Genetic factors are clearly important in selecting 
individuals who develop this unique disease of the airways. The net result is the secretion of a specific 
set of cytokines that drive the inflammatory response. 
While our knowledge about what initiates asthma has grown enormously, we know relatively little 
about those factors, genetic or environmental, that determine disease severity. It should be remembered 
that 10% of asthma patients with severe disease account for 50-60% of the total health costs. 
It is our hope that at this meeting of the BALR, we will discuss factors that initiate and maintain 
asthma but especially those that are associated with deteriorating disease and severe asthma. With the 
advent of new cell and molecular technologies applied to this disease, there is much to be discovered. 
Some of this will be described in what, we are sure, will be a most enjoyable and stimulating meeting. 
We are grateful for the generous support of Astra Pharmaceuticals Ltd., CIBA Laboratories, Pfizer 
Ltd., Pharmacia+Upjohn Ltd, GlaxoWellcome Ltd and Zeneca Pharmaceuticals who sponsored this 
meeting. 
J. M. CORNE 
S. T. HOLGATE 
University Medicine 
Southampton General Hospifal, U.K. 
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The role of T-cell-derived cytokines in allergic disease 
S. ROMAGNANI 
Institute of Infernal Medicine and Immunoallergology, University of Florence, Italy 
The mechanisms accounting for the joint involvement of IgE-producing B-cells, mast cellslbasophils 
and eosinophils in the pathogenesis of allergic reactions have remained unclear until the existence of 
polarized forms of the specific immune response, based on their profile of cytokine secretion, was 
described. Type 1 helper CD4+T-cells (Thl) secrete interleukin (IL)-2, tumour necrosis factor (TNF)-/? 
and interferon (IFN)-y and are the principal effector of phagocyte-mediated host defence, which is 
mainly raised by intracellular parasites. Type 2 helper CD4+ T-cells (Th2), on the other hand, produce 
IL-4 which stimulates IgE and IgGl antibody production, IL-5 (an eosinophil-activating factor), IL-10 
and IL-13, together with IL-4, inhibit several macrophage functions. Therefore, the Th2 cell is mainly 
responsible for phagocyte-independent host defence against certain nematodes, as well as an excellent 
candidate to explain the association of mast cells, eosinophils and IgE-producing B-cells in the 
pathogenesis of allergy. 
In the last few years, strong evidence has been accumulated to support the possibility that 
allergen-specific Th2 cells play a critical triggering role in the induction of allergic inflammation (1): 
allergen-specific T-cell clones, particularly those generated from the peripheral blood of patients with 
severe atopic disorders, usually exhibit a Th2-like profile (2); the majority of T-cells present in the 
target organs of allergic patients express mRNA for IL-4 and IL-5, but neither IL-2 nor IFN-7 mRNA 
(3); allergen challenge results in the activation and recruitment of allergen-specific Th2-like cells at both 
bronchial and nasal mucosa level (4); successful specific immunotherapy associates with shifting of 
allergen-reactive Th cells from the Th2-like to the Thl-like cytokine profile (5); allergen-reactive Th2 
cells expressing membrane CD30, an activation marker preferentially associated with the production of 
Th2-type cytokines, are present in the circulation of allergic patients during seasonal allergen exposure, 
and high levels of soluble CD30 are detectable in the serum of many patients with atopic disorders. 
The mechanisms responsible for the development of allergen-reactive Th2 cells in atopic subjects 
have not yet been clarified. In both in vivo and in vitro systems, IL-4 appears to be the most dominant 
factor in determining the likelihood for Th polarization. Accordingly, IL-4-gene-targeted mice fail to 
generate mature Th2 cells in vivo and to produce IgE antibodies, suggesting that early IL-4 production 
by a cell type distinct from the Th2 cell must be involved. Possible candidates include mast 
cells/basophils and eosinophils, which have been shown to release stored IL-4 in response to FceR 
triggering, the CD4+NKl. 1 +T-cell subset, the CD8 + Tc2 cells, or the naive CD4+ Th cells 
themselves. The CD4 + NKl . 1 + T-cell subset represents a specialized population of CD4 + T-cells 
particularly effective in producing cytokines, which are absent in SJL mice that do not produce IgE. 
Recently, NK1.l + cells able to produce high amounts of IL-4 have been demonstrated in human fetal 
liver and human fetal thymus, and unusually high numbers of IL-4-producing CD4+ CD8 + NKl . 1 + 
cells have been found in the peripheral blood of one patient with severe atopy. CD8+ T-cells able to 
induce IgE synthesis have also been detected in both patients with severe atopy and HIV-infected 
individuals. The possibility that the source of IL-4 required for Th2 development is the naive 
CD4+T-cell itself is also supported by several findings. First, low-intensity signalling of TCR, such as 
that mediated by low peptide doses or by mutant peptides, led to secretion of low levels of IL-4 by 
murine naive T-cells. Second, human CD45RA+ (naive) adult peripheral blood T-cells, as well as 
human neonatal T-cells, develop into IL-4-producing cells in the absence of any pre-existing source of 
IL-4 and in spite of the presence of anti-IL-4 antibodies. Finally, high proportions of T-cell clones 
showing a clear-cut Th2 profile of cytokine production could be generated from single CD4+ T-cells 
isolated from thymus of small children. Moreover, high numbers of CD4+ and CD8+ T-cell clones 
showing a Th2-like profile could also be derived from cord blood mononuclear cells of newborns with 
atopic parents. These data suggest that the maturation of naive T-cells into the Th2 pathway mainly 
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depends on the levels and the kinetics of IL-4 production by naive T-cells themselves at priming (and 
in some cases is further influenced by NKl. 1 + cells and/or CD8+Tc2 cells). The IL-4 production at 
priming may be determined by: (1) the genetic background of the individual; and (2) the nature and the 
intensity of TCR signalling by the peptide ligand. An overexpression of IL-4 gene, as well as of other 
cytokine genes (IL-3, IL-5 GM-CSF and IL-g) located together with IL-4 and IL-13 within the same 
cluster of chromosome 5, may account for the production of cytokines involved in the allergic 
inflammation, and therefore explain the persistent histological, pathological and clinical aspects of 
allergic disorders. 
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Asthma is a chronic inflammatory disease of the airways which is associated with eosinophil 
infiltration, reversible airway narrowing and enhanced responsiveness to allergens or other stimulants. 
The ability to respond to glucocorticoids is used also to distinguish between diagnosis of asthma and 
that of chronic airflow limitation caused by smoking and, as such, asthma is usually described as a 
glucocorticoid-responsive disease. However, there are a few patients with all the clinical features of 
asthma who appear to respond poorly or not at all to glucocorticoids. Another, much larger, group of 
patients require unacceptably high doses of glucocorticoids to maintain control of the disease. Not all 
these patients may have glucocorticoid-resistant asthma (GRA) and a diagnosis of such must only be 
made when all other factors which may worsen asthma-like symptoms are discounted. A similar defect 
in glucocorticoid-responsiveness has also been reported in patients suffering other diseases which are 
treated by glucocorticoid therapy, including rheumatoid arthritis, systemic lupus erythematosis and 
transplant rejection. 
DEFINITIONS OF GRA 
Clinically, GRA is usually defined as a failure of morning PEFR to increase by more than 15% after 
40 mg prednisolone day - ’ for 14 days where reversibility is shown with P-agonists. It is important to 
make a correct diagnosis of GRA as the available treatments are toxic in themselves, These drugs 
include methotrexate, cyclosporin A, rapamycin and gold which are used either to totally replace 
glucocorticoids or to reduce the oral glucocorticoid load. Ideally, if the patient is truly glucocorticoid- 
resistant, they should not be prescribed glucocorticoids. 
FACTORS AFFECTING A DIAGNOSIS OF GRA 
The first group of six GRA patients were described by Schwartz in 1968. This cohort required large 
doses of oral prednisolone which failed to control their symptoms and which had only mild 
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Cushingoid-like symptoms. Since this time, a number of groups have described similar subjects whose 
skin, blood and airways fail to respond to exogenous steroids. GRA has not been found to correlate 
with age, gender, atopic status, duration of asthma or the total duration of glucocorticoid therapy. 
These subjects do, however, respond to glucocorticoids since the HPA axis and the regulation of most 
metabolic functions, including plasma cortisol, tend to be normal and subjects show Cushingoid 
features. 
This group of patients are different from those suffering from primary glucocorticoid-resistance 
where there is a defect in the primary sequence of the glucocorticoid receptor leading to either a failure 
of the receptor to bind the ligand, or for the receptor to bind to other transcription factors or the basal 
transcription apparatus. 
It is necessary to eliminate the various factors that may interfere with glucocorticoid-responsiveness 
and these include: (1) a wrong diagnosis of asthma; (2) insufficient glucocorticoid reaching the airway; (3) 
continuing exposure to sensitizing agents; (4) unrecognized aggravating agents; (5) excessive use of 
P-agonists; and (6) a failure to take treatment. Usually the best method of analysing these factors is to 
bring the patient into hospital. Correct diagnosis allows optimum treatment, and also provides a 
well-defined group of subjects in which to investigate the molecular mechanisms of glucocorticoid action. 
ESTABLISHING A CORRECT DIAGNOSIS 
1. Many asthmatics are diagnosed early on in life and the definition is not queried in later life. The 
correct diagnosis must be confirmed and this means ruling out COPD, episodes of laryngeal stridor 
or vocal cord dysfunction, hyperventilation, endobronchial lesions as well as factitious asthma. 
Furthermore, many subjects can simulate severe attacks. 
2. It is necessary to ensure that the subjects are receiving an adequate amount of steroid at the airway. 
Is the patient using the correct device in the correct manner? Is the dose high enough? 
3. It is necessary to remove continuing exposure to any possible inducing agents. To this end, a 
knowledge of the subject’s allergens/sensitizers may be required. Removal of house dust mites (clean 
bedding), pets and potential occupational exposure to these potential allergens is required. 
4. Potential aggravating factors must also be removed. Gastroesophageal reflux may be an aggravating 
factor for asthma, and treatment sometimes improves the steroid responsiveness. Obstructed sleep 
apnoea and rhinitis with post-nasal drip should also be eliminated as causes of steroid-insensitivity. 
5. Drugs, such as aspirin and related compounds and P-blockers, make asthma worse. Aspirin 
sensitivity must be checked. Only rarely are P-blockers now being prescribed to asthmatics as the 
deleterious side-effects are well known to reduce the intake of large doses of P-agonists. Regular 
high doses of P-agonists may affect the response to steroids in some patients. Removal of drugs 
rarely makes much difference but may be important when allergen avoidance is also undertaken. 
6. Are they taking the glucocorticoid? 
Once these possible compounding factors are taken into account and the subject still fails to respond 
to high doses of oral steroids, a correct diagnosis of steroid-resistant asthma is warranted. 
CASE HISTORY 
The patient, a 63-year-old retired research chemist, had been followed-up in the Brompton Hospital 
for 34 yr for asthma. In 1962, he presented with a 5-yr history of intermittent wheeze and dyspnoea 
which was worse in the cold and had gradually become more persistent and associated with cough. 
His PEFR at this time was 100 1 min - ’ (predicted value 480 1 min - ‘). He was treated with 
prednisolone 40 mg daily and aminophylline suppositories with gradual but partial improvement. 
He remained reasonably well taking prednisolone 3-10 mg day- ’ but continued to exhibit 
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considerable airways obstruction, with PEFR 190-320 1 min - ’ (morning pre-bronchodilator). In 
1972, he was admitted in status asthmaticus following an upper respiratory tract infection and 
was treated with intravenous hydrocortisone 800 mg daily for a week followed by prednisolone 
40 mg daily. He was subsequently maintained on prednisolone 3-10 mg daily. He improved 
symptomatically but continued with significant airways obstruction (PEFR 180-290 1 min - ‘, 
morning pre-bronchodilator). In 1974, he suffered from a further acute severe exacerbation of 
asthma with unrecordable PEFR. He was treated with intravenous hydrocortisone and pred- 
nisolone, and nebulized salbutamol. He was subsequently commenced on inhaled beclomethasone 
dipropionate (high dosage, using a spacer device) along with inhaled salbutamol, and oral 
glucocorticoids were tailed off. Between 1974 and 1990, he remained stable but symptomatic, with 
morning PEFR values 200-260 1 min - ‘. In 1990, he was admitted with an exacerbation of asthma 
associated with purulent sputum and left lower lobe consolidation. Oral prednisolone was 
recommenced for 4 months then gradually discontinued. Since 1990, he has been maintained on 
inhaled beclomethasone dipropionate (4000 lug daily) by metered dose inhaler using a spacer device. 
Records of PEFR over this period showed typical values of 180-220 1 min - ’ (morning) and 
240-260 1 min - ’ (evening). 
He had worked as a research chemist but there was no evidence of exposure to industrial sensitizing 
agents. He had never smoked. There was no history suggestive of aspirin sensitivity, rhinitis, eczema, 
oesophageal reflex or sleep apnoea. He had never kept pets, including birds, at home. 
Full blood count showed a mild neutrophilia, and eosinophilia total serum IgE concentration was 
184 IU ml - ‘. Skin prick tests to extracts of common aeroallergens showed a wheal reaction (15 min) 
in excess of the negative control to cat dander (9 mm), and dog dander (4 mm), feather extract (3 mm) 
and house dust mite (10 mm), but not grass pollen, tree pollen or Aspergillus sp. These were confirmed 
by RAST testing. 
This patient is typical of a minority group of severe asthmatics who continue to exhibit poor lung 
function despite high dosages of inhaled or systemic glucocorticoid therapy, and despite clear 
reversibility of airways obstruction in response to inhaled P-agonists. 
INDUCTION OF GLUCOCORTICOID-RESISTANCE 
The molecular basis of glucocorticoid action has been extensively studied. Glucocorticoids act by 
binding to, and activating, a cytoplasmic receptor which then translocates into the nucleus where it can 
repress the transcription of a wide variety of pro-inflammatory mediators such as cytokines and 
chemokines. Classically, GR acts by binding to a specific sequence of DNA (GRE) upstream of the 
transcription start side, and induces transcriptional up- or downregulation of glucocorticoid- 
responsive genes. The activated GR may also interact with other transcription factors which belong to 
the leucine zipper class of DNA-binding proteins by a direct protein-protein interaction, thus 
modulating an effect that they would otherwise have on gene transcription. This appears to be a key 
mechanism whereby glucocorticoids exert their anti-inflammatory actions. 
The interaction was first demonstrated for the collagenase gene which is induced by the transcription 
factor activator protein-l (AP-l), which is a heterodimer of Fos and Jun oncoproteins; AP-1 binds to 
a specific DNA binding site (TRE). Steroids are potent inhibitors of collagenase gene transcription 
induced by TNFa and phorbal esters which activate AP-1; AP-1 forms a protein-protein complex with 
activated GR and this prevents GR interacting with DNA and thereby reduces steroid responsiveness. 
GR may interact with other transcription factors that are activated by activated by inflammatory 
signals, including nuclear factor-kappa B (NF-KB) in a similar manner. 
Glucocorticoids inhibit the transcription of several cytokines that are relevant in asthma, including 
IL-lp, TNFa, GM-CSF, IL-3, IL-4, IL-5, IL-6 and IL-8. These effects may be mediated directly via 
interaction of CR with a nGRE in the upstream promoter sequence of the cytokine gene or by 
inhibition of AP-1 or NF-k-B DNA binding, resulting in reduced gene transcription. There may be 
marked differences in the response of different cells and of different cytokines to the inhibitory action 
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of glucocorticoids, and this may be dependent on the relative abundance of transcription factors. Thus, 
in alveolar macrophages and peripheral blood monocytes, GM-CSF secretion is more potently 
inhibited by glucocorticoids than IL-l/? or IL-6 secretion. Furthermore, there may also be differences 
in the glucocorticoid sensitivity of different target cells, depending upon the relative balance of 
transcription factors. 
Although complete steroid resistance is uncommon, there may be a spectrum of steroid responsive- 
ness in inflammatory diseases. This may reflect several mechanisms that are secondary either to disease 
activity itself or to the effects of therapy. Downregulation of GR in circulating lymphocytes after oral 
prednisolone has been demonstrated in normal individuals. Whether high local concentrations of 
inhaled glucocorticoids reduce GR expression in surface cells of the airway, such as epithelial cells, is 
not yet certain. It is possible that certain individuals may be more susceptible to the effects of 
downregulation. If effective GR density is reduced by direct interaction with other transcription 
factors, such as AP-1 and NF-KB, then the downregulatory effect of glucocorticoids on GR would be 
expected to have a greater functional consequence. 
Several inflammatory cytokines, including IL-ID, IL-6 and TNFa, activate AP-1 and NF-KB in 
human lung. As all these cytokines are known to be secreted in asthmatic inflammation, this suggests 
that these transcription factors will be activated in the cells of asthmatic airways. These activated 
transcription factors may then form protein-protein complexes with activated GR, both in the 
cytoplasm and within the nucleus, thus reducing the number of effective GR and thereby decreasing 
steroid responsiveness. In a model in vitro system, increased expression of c-Fos or c-Jun oncoproteins 
prevents the activation of mouse mammary tumour virus promoter by GR, thus creating a model of 
steroid resistance. Similar data has been shown using reporter gene assays for the regulation of NF-KB 
activity. Overexpression of the NF-KB subunits, ~65 and ~50, reduces the ability of glucocorticoids to 
repress KB-driven gene transcription. In addition, the interaction between these transcription factors in 
regulating glucocorticoid action has been demonstrated. A dose of dexamethasone which inhibits either 
an AP-1 or an NF-KB-driven reporter system when either c-Fos or ~65 are expressed singly, failed to 
have any effect on either reporter system when c-Fos and ~65 were expressed together. Thus, in asthma, 
when increased expression of a number of these inflammatory transcription factors are expected, the 
effectiveness of glucocorticoids is likely to be markedly reduced. Any reduction in glucocorticoid 
responsiveness would be greater as the intensity of asthmatic inflammation increased and may 
contribute, for example, to the failure of oral or intravenous glucocorticoids to control acute exacer- 
bations of asthma. Once the inflammation is brought under control with large doses of oral glucocor- 
ticoids, steroid responsiveness increases again, so that lower doses of inhaled or oral glucocorticoids are 
needed to control inflammation. In subjects with glucocorticoid-resistant asthma, increased expression 
of some of these transcription factors could lead to a failure of cells to respond to glucocorticoids. 
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Cellular mechanisms of glucocorticoid resistance 
S. J. LANE 
Deparfmenf of Allergy and Respiratory Medicine, United Medical and Denfal Schools (UMDS) of Guy’s and 
Sf Thomas’s Hospifals, London, U.K. 
Resistance to the anti-inflammatory effects of the glucocorticosteroids (GCS) has been documented in a 
wide variety of inflammatory disease states including chronic bronchial asthma (l), rheumatoid arthritis 
(RA), (24), the suppression of renal transplant rejection (56) and the nephrotic syndrome (78). 
Although a relatively rare phenomenon, the lack of therapeutic response to GCS poses a difficult 
therapeutic problem in those patients who are afflicted. For many years, investigators have recognized 
that the elucidation of the mechanisms underlying this phenomenon may yield important clues as to the 
fundamental actions of GCS in inflammation. For experimental purposes, we have defined corticosteroid- 
resistant (CR) asthma as an improvement in FEV, of less than 15% after a 14-day course of 40 mg of 
prednisolone, whereas corticosteroid-sensitive (CS) asthma has been defined as an improvement of 
greater than 30% in FEV, after a similar course of prednisolone (9). CR asthma is associated with disease 
chronicity, a more frequent family history of asthma and impaired in vitro and in vivo responsiveness of 
peripheral blood mononuclear cells (PMBC) to the suppressive effects of glucocorticoids (1,9-13). 
IN VITRO CELLULAR DEFECTS IN CR ASTHMA 
Phenotypic differences in mononuclear cell populations have been described in CR asthma. In 
monocytes derived from patients with CR asthma, there is failure of steroids to inhibit complement 
receptor expression, mononuclear cell colony growth and the generation of a neutrophil priming 
activity (NPA) (9-12). In T-lymphocytes from CR asthmatics, there is enhanced IL-2 and HLA-DR 
receptor expression associated with decreased suppression by steroids of proliferation and IFNy and 
IL-2 generation which is partially reversible by cyclosporin (13). 
IN VW0 CELLULAR DEFECTS IN CR ASTHMA 
We have demonstrated decreased suppression by prednisolone of macrophage, T-lymphocyte and 
eosinophil infiltration into the cutaneous tuberculin response in CR as opposed to CS subjects which 
was not associated with differences in vascular adhesion molecule expression (14). Leung has 
demonstrated reduced suppression of eosinophils and T-cells infiltration into the bronchoalveolar 
lavage (BAL) fluid after prednisolone therapy in CR subjects. This was associated with reduced 
suppression of T-cell-derived L-4 and IL-5 generation suggesting defective Th2 cytokine regulation in 
CR asthma (15). Brown demonstrated that the cutaneous vasoconstrictor response to beclomethasone 
dipropionate was significantly reduced in patients in CR asthma as opposed to patients with either mild 
or severe steroid-dependent CS asthma; however, no cellular analyses were performed on these biopsies 
(16). The above in vitro and in vivo defects appear to be confined to the ‘inflammatory cell’ population 
and are not seen in all steroid-responsive tissue, e.g. the hypothalmic-pituitary-adrenal axis and bone, 
indicating that these patients are at risk of ‘Cushingoid side-effects’ (17,18). 
MECHANISMS OF STEROID ACTION IN INFLAMMATION 
Steroids induce as many genes as they suppress. Steroids induce gene expression by direct interaction 
of the glucocorticoid receptor (GR) with DNA (the glucocorticoid-response element or GRE) (19). 
There is no all-inclusive model of gene expression by steroids; however, most inflammatory cytokines 
are extremely sensitive to their suppressive effects (20). This suppression has been shown to be 
independent of DNA binding of the GR (21). In activated cells, inflammatory cytokine gene expression 
is unregulated by transcription factor proteins [AP-1 (Fos/Jun) and NFKB] by direct binding of these 
proteins to promoter regions of the genes involved. Recent work has demonstrated that steroids 
suppress cytokine gene expression, and thereby inflammation, by sequestration of these factors, thus 
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preventing their subsequent interaction with DNA (21). Co-immunoprecipitation, gel-shift and 
transient transfection technology has demonstrated that steroids inhibit AP-1 inducible genes by direct 
interaction of the GR with AP-1 at protein-protein level (22-25). In the case of NFlcB-inducible genes, 
steroids induce the formation of 1lcB which serves to prevent the nuclear localization of NFk-B, thus 
attenuating the pro-inflammatory effects this factor would have had on subsequent cytokine gene 
activation (26). 
MOLECULAR MECHANISMS OF STEROID RESISTANCE IN BRONCHIAL ASTHMA 
There are no differences in the pharmacokinetic profile to an oral dose of prednisolone in CR as 
opposed to CS subjects (27). In addition, no differences were detected between these groups in terms 
of the ligand binding or nuclear translocation properties of their GRs (28). Furthermore, there is no 
difference in the primary structure of the GR by chemical mutation analysis and by direct sequencing 
(29,30). We have recently demonstrated impaired DNA binding of the GR in the total mononuclear 
population (31). The binding characteristics indicate increased intra-nuclear sequestration of the GRs. 
This sequestration may be caused by AP-1 as there is increased NA binding and synthesis of AP-1 in 
these cells (32). Therefore, a picture is emerging that the molecular defect underlying CR asthma may 
be related to increased levels of the pro-inflammatory transcription factor AP-1. This may overcome 
the suppressive effects of what is a limited number of GRs in a given cell. 
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Treating the patient with chronic severe asthma 
J. G. AYRES 
Heartlands Hospital, Birmingham, U.K. 
Patients with chronic severe asthma are numerically small compared to the bulk of patients with this 
common condition, but occupy a considerable amount of NHS time, costs and resources. It has been 
estimated that the 10% or so of patients with severe asthma consume up to 60% of the direct health 
costs for asthma. Patients with severe asthma can be classified into three main clinical groups: 
1. Those who are oral-steroid dependent; 
2. Those in whom there is a significant component of irreversible airway narrowing; and 
3. Those with Brittle asthma. 
There is clearly overlap between these groups, not only clinically but mechanistically. For instance, 
steroid resistance may be present (to a greater or lesser degree) in any of these groups. 
BRITTLE ASTHMA 
I will address my comments on the treatment of chronic severe asthma by using Brittle asthma as a 
starting point. There are two types of Brittle asthma. Both are subject to repeated severe, life- 
threatening attacks; the Type 1 patients on a background of wide peak flow variation despite maximal 
(some may say supra-maximal) medical treatment, the Type 2 patients being apparently well controlled 
between episodes. 
Type 1 patients are characteristically women, strongly atopic and with marked associated 
psycho-social problems. Indeed, many are regarded by their physicians as suffering more from a 
psychiatric than a pulmonary disorder, particularly as some are non-compliant with therapy as 
dictated by their physician. They have often, as a consequence, lost confidence in their physician. 
These patients do need more time than most to sort out their asthma and to address, perhaps more 
holistically than is possible in a routine clinic, those issues which appear to cause the most problems 
as regards their asthma, either directly or indirectly. For example, in some, relatively simple 
procedures such as helping them obtain Disability Living Allowance will help improve their asthma 
control. 
TRIGGERS 
Identification of triggering factors must be achieved. Some may have been or continue to be exposed 
to unrecognized occupational factors, while over two-thirds have pets at home, despite positive 
RASTs. Unrecognized food intolerance is common, occurring in over 50% of our patients. Identifica- 
tion by food exclusion and double-blind challenge is difficult and time consuming, and needs the 
inclusion of objective measures of a positive response, such as spirometry, changes in circulating 
eosinophil or mast cell activation products exhaled nitric oxide. Once identified, the patient then has 
the problem of avoiding these foods while maintaining a balanced diet. This may be difficult if done 
without dietary advice as, by avoiding such foods and trying not to add to their steroid-induced weight 
gain, marked reductions in dietary intake of the antioxidant vitamins A, C and E and of selenium and 
magnesium are seen. How relevant this may be to maintenance of bronchial hyper-responsiveness 
remains to be seen, although diets deficient in each of these nutrients/elements have been associated 
with either higher asthma prevalence or, at an individual level, worse asthma. 
PSYCHOLOGICAL FACTORS 
Many of these patients panic as their asthma deteriorates, perhaps not surprisingly as most have been 
previously ventilated for asthma. Their Panic Scores are indistinguishable from those seen in full blown 
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panic disorder, and the symptoms of hyperventilation (which in itself may lead to worsening asthma) 
are difficult to distinguish from asthma and from the effects of B-agonists, on which these patients rely 
to a considerable extent, often to the exclusion of alterations in steroid medication. But as they are 
already taking considerable amounts of inhaled steroids, and as some may indeed be truly steroid 
resistant, it may be difficult for the physician to insist that such behaviour is inappropriate. Many come 
from poor home circumstances either currently or in the past, and 80% have given us a history of 
sexual/physical/mental abuse by a family member either at the time or in the past. We feel that a 
dedicated clinical psychologist plays an essential role in managing these patients. 
SUBCUTANEOUS P-AGONISTS 
As these patients, by definition, have wide peak flow variability, attempts were made in the early 
1980s to treat their varying airway calibre with continuous subcutaneous infusions of P-agonist 
(usually terbutaline). This is an effective treatment in around 50% of patients with significant 
improvement seen in a further 25%, the remainder not benefiting. Patients with chronic severe 
asthma without peak flow variability do not, as a rule, benefit from this treatment. The usual dose is 
of the order of 12 mg daily, the dose being delivered by a Graseby MS26 battery powered infusion 
pump. Side-effects related to P-agonists are surprisingly few, with hypokalaemia, tremor and severe 
cramps being the exception, perhaps suggesting tolerance to side-effects but not to the beneficial 
effects. However, problems at the sites of infusion have become increasingly common over the last 
5 yr (without any change in the formulation of the drug) and seem to be related to the patient’s 
atopic status, as those few who are non-atopic appear not to have problems, and biopsy of the 
infusion sites shows an eosinophilic infiltrate. Latex sensitivity appears not to be the cause. 
Occasionally, the site problems become so severe that the infusion has to be switched to a 
permanent i.v. infusion with all its attendant problems. Despite these problems, many patients refuse 
to contemplate stopping treatment. Why this treatment should work with little evidence of the 
development of tolerance is not clear. Blood levels of terbutaline achieved are similar to those seen 
in individuals taking deliberate overdoses of P-agonists. It is possible that the infused route accessed 
an anatomical subgroup of P-receptors which are not reached by the inhaled route, either as a result 
of more marked airway narrowing or perhaps for a less physical obstructive reason. Animal work 
suggests that such a distribution of receptors does in fact occur and so may partly explain these 
findings. 
CORTICOSTEROIDS 
It would seem reasonable to assume that these patients are, to a degree, steroid resistant, although most 
do show (usually marked) steroid side-effects. This, in effect, demonstrates adequate steroid absorption 
from the GI tract, and prednisolone levels in these patients are compatible with regular use. Some, 
however, seem to require huge doses of steroids (either parentally or orally) to have any benefit and 
rarely show side-effects. Presumably, these are the true steroid-resistant patients and, in these, one has 
to question whether there is any need to continue using oral, or even inhaled, steroids. We do not have 
biopsy evidence of, for instance, differences in cytokine expression in these patients, or even whether 
they still show mucosal eosinophilia even in the presence of systemic steroids at high dose. Until we 
have this evidence (one way or the other), it would be a brave physician who would stop the use of 
steroids in these patients who are at risk from life-threatening asthma. 
THE FUTURE 
Pharmacologically, it is difficult to envisage that any of the pending developments in asthma drug 
development will help in this group. Neurokinin antagonists have been tried in one study of patients 
with more severe asthma and were singularly ineffectual. It has to be borne in mind, however, that 
clinical trials in the accepted sense are difficult or impossible in this group, and a Bayesian approach 
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may be more appropriate. My feeling is that each patient with severe asthma has to be treated as an 
individual, sorting out their own risk factors and dealing with their hopes and aims realistically. 
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Early life origins of asthma 
J. A. WARNER 
University Department of Child Health, Southampton General Hospital, U.K. 
RISING TRENDS IN CHILDHOOD ASTHMA AND RELATED ALLERGIC DISEASES 
There has been an increase in the prevalence and severity of allergic disorders and, in particular, 
asthma in children, although clear-cut epidemiological evidence to support this has been slow to 
accumulate, mainly because of lack of an agreed definition of asthma suitable for population surveys. 
One study from South Wales, using identical ascertainment amongst 12-year-olds, showed a change in 
point prevalence between 1973 and 1988 from 4 to 9% for asthma, 5 to 16% for eczema and 9 to 15% 
for hayfever (1). This increase has occurred in many countries and has been demonstrated in Finnish 
military conscripts (2), in Taiwanese schoolchildren (3), Australian children (4) and adolescent Maoris 
in New Zealand (5). While diagnostic transfer might account for the increase in some of the studies, it 
is clearly not the case for the majority (6). Furthermore, there have been enormous increases in hospital 
admissions for childhood asthma over the last 8-10 yr, with no reduction in severity on admission, no 
increase in re-admission ratio and no evidence of diagnostic transfer (7). A relatively small shift in 
population susceptibility due to changes in the environment could account for the increase in frequency 
of disease and the even greater increase in numbers experiencing severe disease. 
Whilst hereditability forms the basis of the definition of atopy, it is clear that the environment must 
have had a major influence on phenotype (8). If this population shift is to be reversed, detailed study 
of the environmental causes is essential. Longitudinal cohort studies will be required to establish which 
of the many possible factors are critical to the development of allergy and subsequent asthma. The 
ultimate aim of such studies must be to identify avoidable factors which might lead to the 
establishment of protocols of prevention. Many of the assertions about prevention at present are based 
on rather limited, usually retrospective, evidence and, while early results from prospective studies look 
encouraging (9), revealed little or no effect (10,ll). 
FETAL AND NEONATAL IMMUNE RESPONSES 
It is known that mature circulating T-cells can be detected in the fetus by 18 weeks of gestation (12) 
and, therefore, anti 
4 
en exposure via the mother could initiate sensitization and immune memory from 
this early stage [prev ods studies have already shown that food allergen avoidance in the third trimester 
of pregnancy is ineffective - possibly being too late (11,13)]. Our detection of specific cord blood 
mononuclear cell responses to allergen implies antenatal immune activation (14,15). We also have 
evidence that maternal exposure to house dust mite allergen during the third trimester of pregnancy 
results in increased neonatal T-cell proliferation to house mite allergen (16), and that maternal 
exposure to birch pollen after 22 weeks of pregnancy is associated with raised infant T-cell responses 
to birch pollen at birth. Furthermore, house dust mite exposure in the first month, but not the third 
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month, after birth strongly influences the development of house dust mite skin prick test sensitivity at 
1 year of age (16) and wheeze at 3 years of age. From previous studies, this is likely to translate into 
a strong association between allergen exposure during pregnancy and the first month of life with the 
subsequent development of atopic asthma (17). Studies of T-cell activation, specific proliferative 
responses to allergens and the cytokine gene expression and cytokine release of triggered cells from 
terminated fetuses and premature babies are underway to determine whether commencing allergen 
avoidance during the second trimester of pregnancy results in the prevention of these raised responses. 
T-CELLS AND CYTOKINES 
Based initially on studies in mice, allergen responsive helper T-cell clones from allergic individuals have 
been shown to selectively produce cytokines of the IL-4 gene cluster encoded on chromosome 5,31 
namely, IL-4, IL-5, IL-6, IL-10 and IL-13 (Th-2 like). Non-atopic T-cells clones produce IL-2, IFN-7 
and TNF/3 (Th-1 like) (18) whilst subtypes produce IL-3 and GM-CSF (19). These cytokines have a 
wide range of effects, including the activation and recruitment of accessory cells in the allergic response, 
specifically mast cells, eosinophils and basophils. Both in murine models of atopy and in human 
allergy, it has been shown that opposing signals from Th-1 cells producing IFN-7 and Th-2 cells 
producing IL-4 and IL-13 influence CD40-dependent IgE synthesis by B-cells (19-23) whilst IFN-y 
inhibits transformation to this isotype (24). Of particular relevance is that when compared to adult 
T-cells, those from neonates have a reduced IFN-y production after polyclonal stimulation (25-27) and 
the same has been shown for IL-4 production (28). Holt et al. (29) have demonstrated that although the 
IFN-y producing capacity by CD4+ T-cell clones from babies was reduced relative to adults, it was 
significantly lower still in babies born to allergic families. It has also been demonstrated that IFN-1/ 
production by cord blood mononuclear cells is reduced in those newborns with a family history of 
atopic disease (30). We have found raised cord blood T-cell proliferative responses and defective IFN-)I 
production to stimulation with specific allergens in babies who have subsequently developed allergic 
problems in relation to those allergens (14) and these observations have been partly confirmed by 
others (31). We have also found that babies born to atopic asthmatic parents who have developed 
allergic manifestations by 1 year of age, have significantly lower CD4+/CD45RO + (memory) and 
CD4 +/CD25 + (activated) T-cells in the cord blood compared with babies who were born in a similar 
situation but have not developed allergic disease or in babies born to non-allergic parents (15). We have 
demonstrated that by 6 months of age, these differences are lost (32) presumably because the relevant 
T-cell populations have moved into the target organs including the lungs, under the influence of 
post-natal allergen exposure. This trafficking of T-cells has not been properly documented in humans. 
IL-10 is a product of various cell types, including monocytes, B-cells and T-cells, and is associated 
with the differentiation of Th-2 cells. IL-10 inhibits cytokine production, particularly of IFN-y, by 
T-cells and natural killer cells (33). It has been suggested that IL-10 prevents the production of the 
IFN-1/ inducing cytokine, IL-12, by accessory cells. One possible mechanism for our findings of reduced 
IFN-7 production by neonatal T-cells is an imbalance of IL-10 and IL-12 production. 
MATERNAL, PLACENTAL AND FETAL IMMUNOLOGICAL INTERACTIONS 
We believe that there is a powerful maternal and placental influence on the fetal immune response, 
which promotes or suppresses Th-2-like activity, but the nature of this influence is not known. 
Evidence is growing that, during pregnancy, the maternal immune response becomes heavily biased 
towards Th-2-phenotype, with increasing IL-4 and IL-10 during gestation being detected in the murine 
system. Clinically, a picture of reduced cell-mediated immunity has been described in pregnancy (34). 
The benefit of this loss of cell-mediated immunity may be a reduction in NK cell activity. These cells 
have been shown to have a role in spontaneous abortion and may attack the trophoblast (35). 
Additionally, IFN-7 is an abortifactant, whose effect may be mediated through the activation of NK 
cells by this cytokine (36). Clearly, Th-1 type cell-mediated immune responses are undesirable for 
maintenance of pregnancy. 
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To date, most evidence of the role of cytokines in pregnancy has been derived from the murine 
system. Dudley et al. showed increasing IL-4 and decreasing IL-2 production by murine maternal 
splenocytes during gestation. However, very low levels of these lymphokines were detected in decidual 
lymphocyte cultures (37). Delassus likewise saw increases in IL-4 and IL-IO, and some increase in 
IFN-7, in peripheral blood mononuclear cell cultures from maternal blood. In the placenta, increases 
were seen in IL-4 but IFN-y did not increase and IL-2 remained low (38). 
Very little work has been carried out on human cytokine production in pregnancy. We have recently 
performed a study investigating T-cell proliferative responses and cytokine production from 16 fetuses 
in the second trimester (15-24 weeks gestation) and 35 babies in the third trimester (26-34 weeks 
gestation). FACS analysis of fetal T-cells showed that whilst CD25 + T-cells are virtually undetectable 
at 15 weeks gestation, at 20 weeks they are approximately 50% of the levels at full term. Proliferative 
responses to PHA were significantly higher in the third trimester than the second trimester (P<O*OOO2) 
and increased with progression through gestation. Even more importantly, we have demonstrated the 
same increase in proliferative response to specific inhalant and ingestant allergens, further supporting 
the theory of intra-uterine priming (39). Despite the difference seen in proliferative responses, there 
were no differences in IFN-7 production during the second or third trimester. However, IFN-7 
production by unstimulated cells was significantly higher in the second than third trimester (PcO.03). 
Thus, it would seem that there is a passive production of IFN-7 by unstimulated cells during the second 
trimester which is lost or controlled by the third trimester. This is supported by Lin et al. who detected 
IFN-y in supernatants from unstimulated fetal-placental cell cultures during the early stages (equiva- 
lent to the first trimester) of murine gestation which was reduced in the second trimester and 
undetectable by the third trimester (40) We hypothesize that the role of non-specific fetal PBMC IFN-7 
production is to counteract the effects of IL-4 produced by the placenta and/or mother. A mechanism 
such as this would be essential to prevent an allergic (Th-2) phenotype in all newborns. Failure of this 
mechanism may underlie the development of atopy. We are currently investigating the materno- 
placental-fetal relationship on cytokine production during pregnancy with particular reference to the 
development of atopy. 
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The genetics of asthma 
E. R. BLEECKER 
University of Maryland, School of Medicine, U.S.A. 
Asthma is a heterogeneous disorder characterized by reversible airflow obstruction and bronchial 
hyper-responsiveness (BHR) to a variety of environmental stimuli. A genetic component in asthma 
is suggested by familial aggregation and twin concordance rates. The clinical expression of asthma 
is influenced by the extent and duration of environmental exposures. Although asthma is difficult 
to characterize, several features closely associated with this disorder are easily measured and 
objectively defined. Recently, the basis for genetic susceptibility to bronchial BHR and atopy has 
been the focus of intensive study since they are important components of the asthma phenotype. 
Evidence suggests that there is a strong heritable predisposition for both BHR and atopy, as well 
as to asthma. 
During the last several years, there have been major advances in understanding the genetic basis 
using several approaches. Genome-wide searches using informative polymorphic markers that span the 
genome at relatively short intervals (lo-15 cm) are underway. The collaborative study on the Genetics 
of Asthma has recently completed such a search in the first 162 affected sib pairs and their parents. All 
affected individuals met strict criteria for the diagnosis of asthma, which included a doctor’s diagnosis 
of asthma, presence of asthma symptoms, evidence of BHR or reversibility of airflow obstruction, and 
no significant smoking history. Families were genotyped for 360 microsatellite markers. The major 
objective of this study was to conduct a genome-wide screen and identify all loci or chromosomal 
regions that contribute to the development of asthma in families of different ethnic/racial backgrounds. 
Preliminary evidence for linkage has been obtained for several chromosomal regions which contain a 
number of potential candidates. In addition to identifying regions for further fine-mapping studies, this 
study suggests that genetic susceptibility to asthma differs between ethnic groups. These studies will 
provide information about susceptibility loci in different racial groups and populations. 
In addition, various chromosomal regions that have candidate genes that are relevant to asthma 
and allergy have been studied. Linkages to chromosome 5q which contains numerous candidate 
loci including the IL4 cytokine group and 12q, where there are genes for interferon gamma and 
nitric oxide synthase, are important areas for further investigation. Our group has shown that 
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genetic loci determining a significant portion of the observed biologic variability in bronchial 
responsiveness and serum IgE were shown to be co-inhibited, and these traits have been mapped 
to chromosome 5q31-q33.16. In addition, there is evidence for a major gene for susceptibility to 
asthma mapping to this same region, where there is a cluster of cytokines and interleukin genes. 
Additional markers have been genotyped in this region in 92 Dutch families ascertained through a 
parent with clinical asthma. The probands were first studied approximately 25 yr ago so that 
age-related changes in the asthma phenotype were not a confounding factor in the analysis. Sixty 
percent of families are linked to this region with a multipoint of LOD of 7.6 at 6cm from D551480. 
The cytokine cluster of genes fall within the confidence interval for this linkage and further studies of 
IL9 as a candidate gene were performed. A novel polymorphism in exon 5, C to T nucleotide 
substitution at position 4130, that results in an amino acid change (Thr to Met) was found by direct 
DNA sequencing of probands. Probands and spouses (non-asthmatic) were evaluated in the 26 
families that show the strongest evidence for linkage to 5q. The frequency of this polymorphism is 
similar to probands [21*7% are CT, freq(T) = 10*9%] and in spouses [ 19.5% are CT, freq(T) = 9*8%]. 
Geometric mean IgE levels were low in both groups (< 100 IU) and not significantly different, 47 IU 
in Cc individuals vs. 38 IU in CT individuals. Thus, this IL9 polymorphism is not related to the 
regulation of elevated IgE levels in these asthmatic Dutch families. 
Thus, significant progress has been made towards identifying genes important in susceptibility to 
asthma. There are now several chromosomal regions that show linkage to asthma and associated 
intermediate phenotypes. It is clear that there will be more than one gene that contributes to the 
development of asthma and allergy. These genetic mechanisms may be different in various racial and 
population groups. Gene-gene interactions may also confer susceptibility to asthma. These studies in 
genetics of asthmas should provide a new approach to understanding basic mechanisms in the 
development of this disease, may lead to new therapies in asthma and allergy, and result in tests for 
early disease identification of individuals at risk. 
The effect of ambient air pollution of airway function 
T.SANDSTR~M 
Deparfmenf of Pulmonary Medicine and Allergology, University Hospital of Norfhem Sweden and Nafional Insfifufe of 
Occupational Health, Medical Division, Umed Sweden 
Increasing attention has been focused upon adverse health effects of air pollution. The problem has been 
long known in work places such as mines and certain factories. The health effects of the London fogs 
attracted considerable attention decades ago, and led to an increased concern of the importance to limit 
their pollution of ambient air generated by combustion. Common components in air pollution, dis- 
charged during burning of fossil fuels in motor vehicles for heating and power generation, are nitrogen 
dioxide (NO,) carbon monoxide (CO), hydrocarbons, carbon particles and fly ash. Ozone (0,) is a 
secondary pollutant generated during the interaction of irradiation from the sun and various components 
in polluted air layers. The clinical observations of suspected unwanted biological effects associated with 
air pollution has led to numerous epidemiological studies to help clarify the questions raised. Such studies 
were originally small scale and not fully controlled, leading to more large-scale, well-controlled studies. 
From such studies, it has been suggested that an increase in airway symptoms, airway infections, 
deterioration of asthma, COPD, hospital admissions and even an increased death rate has been associated 
with common air pollutants such as nitrogen dioxide, ozone and particulate air pollution. Older studies 
from extremely highly polluted areas have suggested outbreaks of asthma-like symptoms and possibly 
allergies. While it is accepted that asthma may deteriorate with increased air pollution, considerable 
research is focused upon whether air pollution indeed induces asthma and allergy. Similar questions are 
raised regarding allergies, and a lot is to be learned by current and future research. 
A shortcoming with epidemiological studies is often the problem to isolate the influence of a 
single factor on the study parameters. Since man encounters a large number of potentially harmful 
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factors, it can therefore be very difficult to avoid interacting and confounding factors. The use of 
specially designed challenges with single air pollutants in exposure chambers has therefore become 
favoured in experimental studies of the biological effects of air pollutants. The specially designed 
exposure chambers have given an opportunity to create controlled and standardized atmospheres 
where factors such as work load, breathing pattern, duration of exposure and number of exposures 
can be controlled. Such studies mimicking indoor and outdoor environments have been performed 
in healthy volunteers, asthmatics, and COPD patients as well as other populations. A considerable 
body of experimental research has today increased the understanding of the effects of ambient air 
pollution on airway function. Pulmonary effects have been explored with tests of airway mechanics, 
measurements of airway hyper-responsiveness, bronchoalveolar and nasal lavages, measurements of 
soluble components in lavage fluids and peripheral blood, as well as, more recently, airway mucosal 
biopsies. Such studies have shown that asthmatics are far more sensitive than healthy subjects in 
developing bronchoconstriction and airway hyper-responsiveness to pollutants such as sulphur 
dioxide and nitrogen dioxide. Nitrogen dioxide concentrations slightly above the ambient levels, 
occurring in work room situations, have repeatedly been shown to induce airway inflammation both 
after single and repeated exposures. Nitrogen dioxide may also effect mucocilliary activity. Today, 
there is still information lacking regarding pro-inflammatory effects of nitrogen dioxide in concen- 
trations of the upper level range in highly polluted ambient air. A major reason for this is the 
considerable shift of interest which has not surprisingly been focused upon ozone effects. Following 
a pivotal study of Koren et al. at the U.S. Environmental Protection Agency, it has been established 
that ozone in concentrations occurring in ambient air during summer smogs are considerably 
pro-inflammatory, inducing reactive actions in a multitude of systems. This is a major research area 
today both in Europe and overseas. Most recently, studies have been performed using not only 
bronchoalveolar lavage techniques, but also adding the much-needed information from bronchial 
mucosal biopsies. This has added novel mechanistic aspects of the induction of inflammation and 
cell recruitment by the common highly oxidative air pollutant. Furthermore, it has only recently 
been explored how the oxidative stress in the airways interacts with important antioxidants in the 
airways, vitamin C, uric acid and glutathione. Ozone causes large consumptions of these protective 
components, resulting in compensatory elevated levels, due to enhanced production rates. It has yet 
to be defined what concentration of ozone in ambient air is safe against unwanted biological effects. 
This concerns effects on respiratory airflow, hyper-reactivity, airway inflammation and lung tissue 
damage. 
Together with the considerable interest in bio-effects of ozone, much attention has been directed 
towards the effects of ambient air particulates during the last few years. It appears most likely that an 
unexpectedly large part of the unwanted effects of air pollution is due to the fly ash. Since in vitro and 
animal studies pay a great deal of attention to the fine and ultrafine particles, it is a considerable 
methodological problem for the epidemiological studies that the measurements in ambient air have 
been very crude, measuring PM 10 and occasionally PM 2.5. Most recently, experimental research in 
man has shown that controlled exposure to diluted vehicle exhaust, in the exposure chamber system, 
induces pro-inflammatory effects in the airways, reflected in bronchoalveolar lavage and bronchial 
mucosal biopsies, at a level previously unsuspected. Obviously a large number of systems are activated 
responding to the particulates, hydrocarbons and other components in the exhaust from diesel engines. 
These early data may well indicate a far more provocative potential in the airways by the particulate 
components of ambient air than previously anticipated. 
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The epidemiology of air-pollution-induced lung disease 
J. M. SAMET 
Deparfmenf of Epidemiology, School of Hygiene and Public Health, Johns Hopkins University, Baltimore, Maryland, U.S.A. 
Air pollution has likely had adverse effects on health throughout man’s history. The use of fire for heating 
and cooking brought exposure to smoke, and the rise of cities concentrated the emissions of pollutants 
from dwellings and from manufacturing facilities within restricted locales. Industrialization and electric 
power generation brought new point sources of pollution, and sometimes immense emissions of 
combustion by-products, particles, nitrogen oxides and sulphur oxides, into adjacent areas where people 
lived and worked. During the 20th century, mobile sources, including cars, trucks and other fossil-fuel 
powered vehicles, created a new type of pollution-photochemical pollution or ‘smog’, first recognized in 
the Los Angeles air basin. The unprecedented growth of some urban areas to form ‘mega-cites’ such as 
Mexico City, Sao Paolo and Shanghai has led to unrelenting air pollution from massive vehicle fleets and 
snarled traffic, and from polluting industries and power plants. During the 20th century, there has also 
been increasing recognition that the problem of air pollution extends into indoor environments. In the 
less-developed countries, exposure to smoke from biomass fuel combustion is widespread today, as in 
past centuries. In the more developed countries, indoor pollutants are generated by man’s activities and 
released from the materials used for construction and in furnishings, and often maintained at unhealthy 
concentrations by building designs which seal pollutants within the building. Exposures received in both 
indoor and outdoor environments are thus relevant to the health of persons with lung disease, and these 
exposures remain relevant in developed and developing countries alike. 
A series of dramatic episodes of intense air pollution associated with obviously excess numbers of 
deaths had shown by the mid-20th century that air pollution can adversely affect the public’s health. 
Epidemiologic studies showed a parallel effect of air pollution on morbidity, and this emerging 
evidence on air pollution and respiratory health promoted regulatory approaches to improving air 
quality in the United States, the United Kingdom and elsewhere. Monitoring data showed trends of 
improving air quality for key combustion-related pollutants such as particles, sulphur oxides and 
nitrogen oxides, while ozone tended to mount as vehicle numbers and usage increased. Nonetheless, 
several lines of evidence suggest that air pollution may continue to adversely affect the public’s 
health in spite of seeming gains for some pollutants. First, recent studies have shown associations 
between levels of air pollutants, particularly particles, and mortality in a number of jurisdictions. 
There are supporting data from parallel studies of morbidity. Second, the frequency of asthma is 
rising worldwide without evident explanation; a role for air pollution, in both indoor and outdoor 
environments, needs to be considered. 
This presentation will address the findings of recent epidemiologic studies on air pollution and 
respiratory health, emphasizing the findings of particulate air pollution and considering the potential 
role of air pollutants in the changing picture of asthma. Epidemiologic studies provide an assessment 
of the adverse effects of pollution exposures, under the circumstances of ‘real world’ exposure, and 
consequently their findings receive substantial emphasis in setting regulations to protect the public’s 
health and in evaluating the impact of the regulations. The exposures are inherently representative of 
the exposures received in the community setting, and the pollutants are inhaled in the form of the 
complex mixtures that actually exist in indoor and outdoor air. Additionally, the community members 
in a study can be selected from the full spectrum of potential susceptibility. There are, however, 
weaknesses of the epidemiologic approach. Exposures to pollutants may be difficult to measure 
accurately, particularly past exposures that may have determined current health, and hence exposure 
estimates in epidemiologic studies are subject to substantial error. The effects of other exposures 
relevant to the health outcome of interest, termed ‘confounding factors’, may not be sufficiently 
controlled, and these extraneous exposures may artefactually increase or decrease the apparent effect 
of air pollution exposure. Epidemiologic studies having inadequate sample size and therefore limited 
statistical power may supply imprecise and uninformative estimates of risk, and not sharply answer 
public health questions. 
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This presentation will review the approaches used by epidemiologists in investigating air pollution 
and asthma. Air pollution, whether outdoor or indoor, could act to increase the frequency of asthma 
either by increasing the incidence of asthma, the occurrence of new cases, or by making asthma more 
severe and thereby adversely affecting nature history. Both outdoor air pollutants, particularly fine 
particulate matter generated by combustion sources, and indoor air pollutants, particularly allergens 
and tobacco smoke, could plausibly increase incidence of asthma or increase disease severity. In fact, 
indoor allergens have been prominently advanced as contributing to the worldwide increase in asthma. 
Changing characteristics of housing in developed countries have been suggested as increasing allergen 
exposure, consequent to the increasingly widespread use of carpeting and to reduction of the rate of air 
exchange between indoor and outdoor air. Definitive data in support of these hypotheses related to air 
pollution have not yet been reported, however. 
These hypotheses need to be tested. Informative studies will need to include rigorous exposure 
assessment, careful characterization of outcome, and sufficiently large sample sizes. The studies should 
include collection of DNA for future determinations of asthma genotype and evaluation of gene- 
environment interactions. Undoubtedly, substantial resources will be needed to conduct informative 
studies. These resources should be made available as morbidity and mortality are mounting and 
solutions may lie in environmental controls. 
REFERENCES 
1. American Thoracic Society, Committee of 
the Environmental and Occupational Health 
Assembly. Am J Respir Crit Car Med 1996; 
153: 3-50. 
2. American Thoracic Society Committee of 
the Environmental and Occupational Health 
Assembly. Am J Respir Crit Care Med 1996; 
153: 477498. 
3. Department of Health Committee on the 
Medical Effects of Air Pollutants. London: 
HMSO, 1995. 
4. Gergen PJ, Weiss KB. Am Rev Respir Dis 
1993; 146: 823-824. 
5. Infante-Rivard C. Am J Epidemiol 1993; 
137: 834-844. 
6. Institute of Medicine, Committee on the 
Health Effects of Indoor Allergens, Division 
of Health Promotion and Disease Preven- 
tion Washington, D.C.: National Academy 
Press, 1993. 
7. Lang DM, Polansky M. N Engl J Med 1994; 
331: 1542-1546. 
8. Newman-Taylor A. Lancet 1995; 345: 296- 
299. 
9. U.S. Environmental Protection Agency, 
Office of Research and Development, and 
Office of Air and Radiation. Washington, 
D.C.: U.S. Government Printing Office, 
1993. 
10. Weiss KB. In Annual Review of Public 
Health (Omenn GS, Cave LB, eds). Paolo 
Alto: Annual Reviews Inc., 1993. 
BALR Young Investigator Competition 
Over-expression of LTC4 synthase in eosinophils accounts for cysteinyl-leukotriene 
over-production in aspirin-induced asthma 
,A. S. COWBURN”, K. SLADEK+, L. ADAMEK+, E. NIZANKOWSKA+, A. SZCZEKLIK~, B. LAM*, 
J. PENROSE*, K. F. AUSTEN*, S. T. HOLGATE’ AND A. l? SAMPSON” 
“University Medicine, Southampton General Hospital, U.K., ‘University School of Medicine, Cracow, Poland, and 
*Harvard Medical School, Boston, U.S.A. 
Aspirin challenge induces severe bronchospasm in a minority (- 20%) of asthmatic subjects due to a 
dramatic rise in cysteinyl-leukotriene (cys-LT) production. Baseline cys-LT production is also 
chronically upregulated in unchallenged aspirin-induced asthmatics. The mechanisms of this upregu- 
lation remains unknown. 
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To identify the cellular sources of cys-LTs, the authors have immunostained for enzymes of the 
leukotriene synthetic pathway and for leukocyte markers in bronchial mucosal biopsies of unchallenged 
aspirin-induced asthmatics (AIA; n= 10) and aspirin-tolerant asthmatics (ATA; n= IO), and in normal 
subjects (N; IZ = 10). Glycol methacrylate-embedded biopsies were sequentially sectioned (2 pm) and 
immunostained with antibodies for 5-lipoxygenase (5-LO), 5-LO activating protein (FLAP), LTA, hydro- 
lase (LTA,H), LTC, synthase (LTCJ), mast cells (AAl), eosinophils (EG2) and a range of cytokines. 
Submucosal immunostaining showed that LTC,S-positive cells were five times more prevalent in 
AIA (11.5 f 2.2 cells mm - 2, than in ATA (2.22 f 0.74 cells mm - 2; P=O*OOO6), and 10 times more than 
in N subjects (1.23 & 0.67 cells min - 2; P=O*OOO3). Co-localization to cell markers indicated that 74% of 
these LTC,S-positive cells were eosinophils, while relatively few mast cells (3%) expressed LTC,S. 
Significantly more eosinophils were present in AIA (39.4 f 8.4 cells mm - 2, than in ATA (12.1 f 4.2 
cells mm - 2; P=O*OO6) or N biopsies (4.4 f 1.4 cells mm - 2; P=O*OOO3), and a greater proportion of 
these eosinophils expressed LTC&S in the AIA subjects. Expression of the eosinophilopoietic cytokine 
interleukin-5, much of it co-localized to mast cells, was higher in AIA (5.00 f 1.32 cells mm - 2, than in 
ATA (1.27 f 0.43 cells mm - 2), suggesting a role in perpetuating eosinophilia in the AIA lung. 
Segmental lysine-aspirin challenge in AIA and ATA subjects did not alter expression of cell markers, 
enzymes or cytokines, but the rise in BAL fluid levels of cys-LTs at 20 min correlated significantly with 
the numbers of LTC,S-positive cells in the bronchial mucosa (rz0.89, P>O*OOl, n= 10). The authors 
have shown that cysteinyl-LT over-production in aspirin-induced asthma is pre-determined by 
over-expression of LTC, synthase in eosinophils in the AIA lung. 
Towards defining the molecular determinants of surfactant apoprotein gene expression: 
studies of TTF-1 and HNF-3/fovkhead proteins in human lung cell lines 
S. GOWAN AND C. D. BINGLE 
DH Department of Toxicology, St Bartholomew’s and the Royal London School of Medicine and Dentistry, London, U.K. 
Studies of the promoter elements of the surfactant apoprotein genes (SP-A to SP-D) which direct the 
appropriate cell type-specific expression to the pulmonary epithelium have identified the TTF- and 
HNF-3/forkhead transcription factors as being functionally important. TTF-1 is a single protein 
expressed in the lung, thyroid and forebrain, whereas HNF-3/forkhead proteins comprise an extended 
family, some of which appear to be lung enriched. The exact tissue distribution of these factors remains 
to be elucidated although both of these protein classes have been shown to be expressed within the 
pulmonary epithelium. The DNA binding specificity of the HNF-3/‘rkhead proteins is highly 
conserved suggesting that data from transactivation studies performed in vitro must be correlated with 
the in vivo expression pattern of the specific family members if an absolute role for each in the 
regulation of the SP genes is to be defined. Previously, the authors have cloned human TTF-1 and 
HNF-3a from the SP-A expressing adenocarcinoma cell line, H441. These studies have now been 
extended by screening a number of human lung cell lines by a combination of gel-mobility shift and 
reverse transcription polymerase chain reaction (RT-PCR), for expression of TTF-1 and HNF-3/ 
forkhead proteins as well as SP-A. 
Robust expression of TTF-1 was found in H226 and H358 cells as well as in the H441 cells. These 
three lines also express SP-A mRNA, suggesting that TTF-1 may be necessary but not sufficient for 
expression of SP-A. In contrast, expression of HNF-3a was found in all lines tested (> 15) by both 
RT-PCR and gel mobility shift. The gel mobility shift studies suggested that HNF-3/‘orkhead proteins 
other than HNF-3a were also present in certain cell lines. To identify these proteins, additional 
RT-PCR studies were performed. Subsequent sequencing of cloned products identified expression of 
FREAC-1 in H647 cells, the human homologue of HNF-3y in H647, H226 and MOR cells and the 
presence of a novel protein related to mouse Ihd-5 in H841 cells. The authors are presently 
characterizing these additional family members in the hope that it may be possible to further define 
how these factors function in restricting expression of the SP genes to the pulmonary epithelium. 
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Urate consumption by ozone in nasal epithelial lining fluid is subsequently 
compensated for by an adaptive increase in the plasma uric acid pool 
I. MUDWAY’, F.J. KELLY*, A. BLOMBERG+ AND T. SANDSTR~M+ 
“Cardiovascular Research, The Rayne Institute, St Thomas’ Hospital, London, U.K., and %ziversity Hospital of Umeh, 
National Institute for Working Life, Medical Division, Umea, Sweden 
Extra-thoracic removal of inhaled oxidant gases by antioxidants within the epithelial lining fluids 
(ELFs) of the upper airways has been proposed to constitute an important protective mechanism 
which prevents the penetration of harmful oxidant gases to the more sensitive distal lung. Uric 
acid (UA), the predominant water-soluble antioxidant within upper airway ELF, has a high 
intrinsic reactivity toward ozone (0,) and may be particularly important in conferring protection 
against this gaseous pollutant. To define the relationship between inhaled 0, with UA within this 
compartment, human subjects (n= 12) were exposed to 200 ppb 0, or OS-free air on two separate 
occasions. Each exposure was for 2 h using a standard alternating rest and exercise protocol. 
Upper airway ELF was sampled in these individuals by nasal lavage (NL) at the following time 
points: (t’o), pre-exposure; (t/60), 60 min into the exposure; (t’120), immediately prior to the end of 
the exposure period; and (t’60PE), 60 min post-exposure. Blood samples were also obtained at 
these times in order to determine whether events occurring within the nasal ELF impinged upon 
the plasma UA pool. No significant change in the concentration of UA within NL fluid or plasma 
samples from subjects exposed to OS-free air were observed at any of the time points examined, 
relative to their t’0 concentration. Following 60 min exposure to O,, the concentration of UA in 
NL fluid was found to fall significantly: t’0 22.2 (15.831.5) vs. t’60, 14.7 (10.9-16.0) pmol 1 - ‘, 
P=O*OO2. Thereafter, the concentration of UA at the t’120 and t’60PE time points remained 
significantly depressed compared with the t’0 concentration. Notably, however, ELF UA concen- 
tration did not fall further at these times, rather it remained at the new steady-state concentration 
of approximately 70% of the t’0 value. This apparent conservation of the nasal ELF pool 
coincided with an increase in the concentration of plasma UA, occurring during the period t’60 to 
t’120 (293.1 f 116.4 and 317*2* 115.6pmol l-‘, respectively, P= 0.003). These data indicate that 
UA within nasal ELF does react with environmentally relevant concentrations of 0,, and that the 
initial loss of UA from this compartment is rapidly offset by an increase in the circulating plasma 
concentration, suggesting a relatively free movement of UA between these two pools. 
The effect of macromolecules on IL-8 binding and function 
L. S. P. RAMDIN, N. C. SHERON AND J. K. SHUTE 
University Medicine, Southampton General Hospital, U.K. 
Interleukin-8 (IL-8) is an important neutrophil (PMN) chemo-attractant in the lung. Expression of 
IL-8 is increased in a number of allergic and non-allergic inflammatory disorders including asthma and 
cystic fibrosis. The bioactivity of cytokines is influenced by their interaction with macromolecules 
including glycosoaminoglycans (GAGS), immunoglobulins and qmacroglobulin. Previously, the 
authors noted that the interaction of IL-8 with qmacroglobulin prevented the chemokine from 
binding to a heparin affinity column (Perks et al., Respir A4ed 1997; A.43). In this study, therefore, the 
effect of heparin and qmacroglobulin on IL-8 binding and function was investigated. 
The chemotactic response of PMN to IL-8 (10 - * M) in the presence and absence of heparin, in the 
concentration range of 1 ng-lOO pug ml - ‘, was assayed in micro-Boyden chambers. Incubations were 
for 30 min at 37 “C. Migrated cells were fixed and stained for counting. In parallel experiments, PMN 
were incubated with 1.25 nM ‘251-IL-8, in the presence and absence of heparin and a,-macroglobulin, 
in the concentration range of l-100,~g ml- i and 0.1-10 ng ml - ‘, respectively, at 4°C for 1 h. 
Non-specific binding was less than 5% of the total. 
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Chemotactic responses to IL-8 were inhibited by heparin with an IC,, of 3.6pg ml- ‘. Specific 
binding of ‘251-IL-8 was inhibited by heparin with an IC,, of 26 ,ug ml - ‘. a,-macroglobulin reversed 
the inhibitory effect of heparin (I&,) in a dose-dependent manner which was significant at 1 ng ml - ‘. 
Therefore, the authors have identified a potentially important role for heparin and a,-macroglobulin in 
the regulation of IL-8 bioactivity. 
Matrix metalloproteinases cleave CD44 and ICAM- on bronchial epithelial cell lines 
S. RAZA, P. M. LACKIE AND R. C. BENYON 
University Medicine, Southampton General Hospital, U.K. 
Severe damage to the bronchial epithelium is a common feature in asthmatics. The matrix metallo- 
proteinases (MMPs) can degrade all components of the basement membrane, although there is an 
increasing awareness that their activities are not confined to matrix degradation. The effects of MMPs 
on cell adhesion molecules were investigated. Immunohistochemistry and gelatin zymography showed 
that human bronchial epithelial cells and the bronchical epithelial cell line NCI-H292 produce the 
MMPs gelatinase A and B. H292 cells treated with purified human gelatinase A (0.1 ,ug ml - ‘) for 1 h 
showed ~67% and ~75% reduction in cell surface expression of the adhesion molecules CD44 and 
ICAM-1, respectively, assessed using FACS. Treatment with another MMP, stromelysin-1 (0.2,~g 
ml - I), for 1 h resulted in z 70% and z 50% reduction of cell surface CD44 and ICAM- 1, respectively. 
Removal of CD44 and ICAM- was dependent on enzyme concentration and could be inhibited by 
5 mM, 1,lO phenanthroline, an MMP inhibitor, Gelatinase A and stromelysin-1 cleaved CD44 and 
ICAM- in another bronchial epithelial cell line, 16-HBE 140 - Western blotting confirmed the release 
of CD44 and ICAM- fragments into the supernatants of MMP-treated H292 cells. Gelatinase A and 
stromelysin-1 treatment resulted in the release into the supernatant of a ~55 kDa fragment from cell 
surface CD44 (normally 85 kDa and above). Treatment resulted in the release of z 70 and z 65 kDa 
fragments from cell surface ICAM- (normally 90-l 15 kDa) into the supernatant. It is concluded that 
gelatinase A and stromelysin-1 can cleave ICAM- and CD44 in vitro, and may play a role in 
regulating their levels on the epithelial cell surface in vivo. 
Acute inflammatory changes in the bronchial tissue following acute exposure to diesel 
exhaust in healthy human volunteers 
S. S. SALVI’, A. BLOMBERG’, B. RUDELLt, F. J. KELLY*, T. SANDSTROM+, A. J. FREW+ AND 
S. T. HOLGATE’ 
*University Medicine, Southampton General Hospital, U.K., ‘University Hospital of Northern Sweden, Umeii, Sweden, 
and *St Thomas’ Hospital, London, U.K. 
Particulate matter pollution mainly from diesel exhaust has become a matter of increasing public 
concern, but the mechanisms underlying their toxicity are largely unknown. To investigate this, 15 
healthy non-smoking volunteers were exposed at random in an environmental chamber to diluted 
diesel exhaust (300 pgm m - 3 PM,,, 1.5 ppm NO,) or filtered air on two separate occasions for 1 h 
with intermittent periods of rest and exercise. Fibre-optic bronchoscopy and endobronchial biopsy 
was performed 6 h after the end of exposure. The biopsies were processed in GMA, 2,um thin 
sections were obtained and immunostained for PMNs, CD3 +, CD4+, CD8 + cells, mast cells, 
eosinophils, adhesion molecules and their ligands using monoclonal antibodies. The inflammatory 
cells were quantified in the epithelium and the submucosa by computerized image analysis, and 
expressed as cells mm - ’ and cells mm - 2, respectively. 
These results suggest that 6 h following acute exposure to diluted diesel exhaust, there is a significant 
cellular inflammatory response in the airways of healthy human subjects associated with upregulation 
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Cells Air Diesel P value Adhesion mols. Air Diesel P value 
PMNs epi 0.83 3.69 
PMNs sub muc 21.8 59.9 
CD3+ epi 3.8 23.59 
CD3+ sub muc 5.96 24.97 
CD4+ epi 0.36 2.97 
CD4+ sub muc 3.28 13.10 
CD8+ epi 2.47 7.22 
Mast cell sub muc 8.8 32.79 
co.05 ICAM- 48.94 93.24 co.005 
co.005 VCAM-1 0.67 2.21 co.053 
co.05 LFA-1 epi 0.09 5.70 co.005 
co.05 LFA-1 sub muc 1.40 43.95 co.05 
<0*005 
co.05 
co.05 
<0*005 
Results expressed as medians; epi, epithelium; sub muc, submuscosa. 
of adhesion molecules. Exposure to particulate matter may, therefore, contribute to further exacer- 
bation of the underlying cellular inflammation in asthmatics, and contribute to increasing mortality 
and morbidity. 
Interleukin-8 (IL-S) release by primary human alveolar type II cells in vitro: effect of 
neutrophil elastase and cigarette smoke 
I. R. WITHERDEN”, I? GOLDSTRAW+, U. PASTORINO+ C. RATCLIFFE+ AND T. D. TETLEY* 
“Department of Medicine, Ckaring Cross & Westminster Medical School, and ‘Department of Surgery, Royal Brompfon 
Hospital, London, U.K. 
Neutrophil influx during chronic obstructive pulmonary disease and acute lung injury may follow 
release of IL-8 by epithelial cells. Although primary human airway epithelial cells have been shown to 
synthesize IL-8 following stimulation in vitro, it is unclear whether this is true of respiratory epithelium. 
This study aimed to examine IL-8 release by primary human alveolar epithelial type II cells (TII) in vitro 
and the effect of neutrophil elastase (NE) and cigarette smoke (CS). TII were isolated from normal 
regions of human lung tissue removed following lobectomy for carcinoma (n= 11). The TII were plated 
into 96 well plates (1.5 x lo5 cells well - ’ in 10% serum). At confluence (4 days), they were exposed for 
24 h to: NE (1 and 10 pmol); 1 and 5% CS solution (100% generated by passing smoke from one 
medium tar filterless cigarette through 1 ml serum-free tissue culture medium); cytomix (CYT; contain- 
ing lipopolysaccharide, interferon y, ILlp, tumour necrosis factor a); CYT+CS. All samples released 
IL-S, although three were not stimulated by CYT. Both CYT and low NE levels stimulated TII release 
of IL-8 in the remaining samples. Inhibition of TII IL-8 release by 5% CS and 10pmol NE may reflect 
cytoxicity (CS), cell detachment (NE), assessed by 51Cr release, or fragmentation of IL-8 (CS and NE). 
Thus, human TII synthesize IL-8 and are capable of mediating neutrophil inflammation in the lower 
respiratory tract via variable release of IL-8. 
pmol IL-8 ml - ’ conditioned media 
Control 1% cs 5% cs 1 pmolNE 10 pmolNE CYT + 1% cs +5% cs 
1375 2134 598* 1872* 980* 14257” 11035 895** 
(0.84.7) (0.5-7.7) (0.1-3.4) 1.2-6.7) (0.3-2.3) (8.6-25.0) (7.0-16.0) (0.2-1.4) 
Expressed as median (range x 10 - 3); >6 wells condition - ’ sample - ‘, y1= 6-8 lung samples. 
Significance, PcO.05, *vs. control or **vs. CYT-stimulated. Wilcoxon signed rank test for paired data. 
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Aspergihs fumigafus spore binding to hmg epithelial cells and extracellular matrix 
proteins 
I. M. J. BROMLEY AND K. DONALDSON 
Deparfmenf of Biological Sciences, Napier University, Edinburgh, U.K. 
Aspergdlus fimigatus (A.$) is a ubiquitous fungus that is capable of inducing asthmatic attacks and 
of causing allergic bronchopulmonary aspergillosis in asthmatics. In this study, cells of the A549 
alveolar epithelial cell line and extracellular matrix (ECM) proteins (fibronectin, collagen and 
laminin) coated on 96-well plates were examined for ability to bind A.$ spores. Spores adhered in a 
concentration-dependent manner to A549 cells, and this adhesion was enhanced after treatment of 
the cells with interferon-y (IFN-y). All data as mean (SEM) of adherent spores per five fields of 
view: control 242(24), 2500 U ml - ’ IFN-7 391(37). Spores adhered specifically to ECM components 
laid down by A549 cells, and this was increased after treatment of the ECM with H,O,: control 
445(50), 80pM H,O, 662(48). Spores bound specifically and in a saturable manner to purified 
fibrinogen, fibronectin, laminin, type I collagen and type IV collagen. Spore pre-incubation with 
Arg-Gly-Asp tripeptide (RGD) inhibited binding to fibronectin and type I collagen: fibronectin 
control 169(24), 2OOpg ml - ’ RGD 76(2); type I collagen control 268(15), 200 ,ug ml - ’ RGD 154 
(13). This study suggests that the presence of activated epithelial cells and the exposure of basement 
membrane that occur in asthma, along with oxidant stress, may facilitate the colonization of the 
asthmatic lung by A.$ The RGD sequence may be involved in spore binding to some ECM 
components. 
A novel transforming growth factor p2 antisense transcript in mammalian 
lung 
R. K. COKER, G. J. LAURENT, K. DABBAGH, J. S. DAWSON AND R. J. MCANULTY 
Cenfre for Cardiopulmona y Biochemist y t? Respiratory Medicine, University College London Medical School, 
London, U.K. 
During studies investigating the role of the mammalian transforming growth factor j3 (TGFP) 
isoforms in the pathogenesis of respiratory disease, TGFj3, gene expression was examined in normal 
murine, rat and human lung. Six adult mice and six adult rats were killed by pentobarbitone 
overdose. Three animals were used for in situ hybridization and three for Northern analysis. Human 
lung tissue was obtained from two patients undergoing re-section for carcinoma. Only macroscopi- 
tally normal lung peripheral to the resection was used for these studies. Lung tissue was fixed in 
freshly prepared 4% paraformaldehyde in phosphate-buffered saline. Digoxigenin-labelled riboprobes 
and 32P-labelled cDNA probes were synthesized from TGFP isoform-specific cDNA templates. 
TGFP, and TGFP, mRNA transcripts were widely distributed in normal lung, but hybridization 
with the TGFp2 probes yielded unexpected results, with signal obtained using the sense probe but 
little or no signal using the antisense probe. These results were confirmed in all three species 
examined. Dideoxynucleotide sequencing showed that this did not result from incorrect probe 
orientation in the vector, and chemiluminescence assay showed that digoxigenin incorporation in the 
sense probe did not exceed that in the antisense probe. Northern analysis of poly A+ RNA from rat 
lung and murine lung cells using radiolabelled cDNA probes confirmed the specificity of the TGFP, 
probe. 
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Using digoxigenin-labelled riboprobes, it was demonstrated that the antisense riboprobe detects four 
previously described mRNA transcripts, but that the sense riboprobe hybridizes with a 3.2 kb 
transcript not identified previously. The authors propose that this is a novel TGF& antisense 
transcript which may regulate pulmonary TGF& production. 
This work was funded by the Wellcome Trust. 
Treatment of asthma - how much is not too much? 
M. MAMUN*, S. M. ALCOCK+, R. J. PRESCOTT* AND C. K. CONNOLLY* 
“Department of Medicine, University of Newcastle upon Tyne, ‘Memorial Hospital, Darlington, and *Medical Statistics 
Unit, University of Edinburgh, U.K. 
As asthma is a common condition with a genetic component, a survival advantage of one or 
more of the factors of its pathogenesis may be postulated. One hypothesis is that of past 
protection by eosinophils against parasitic infection. The present study has considered another 
possibility; an advantage in heightened airway responsiveness. In this parallel cohort study 
involving 824 asthmatics referred to secondary care [mean FEV, 75.4 ( f 26-S)% predicted, mean 
best FEV, 84.6 ( f 28.6)% predicted, mean actual/best PEF 87.5 ( f 12-l)%], symptoms, pul- 
monary function and mortality over lo- and 5-yr periods (1983-93 and 1988-93) have been 
studied. Symptoms (nocturnal disturbance, restricted activity and bronchodilator usage, as proxy 
for symptomatic wheeze) were plotted against control, as assessed by actual/best FEV, and PEF. 
In all but one of the six plots, symptoms were less in the fourth than the fifth quintile of 
function. The standardized mortality rate (SMR) against the local population was: 1983-93 1.47 
(Cl 1.26-1.71); 1988-93 1.40 (1.15-1.70). In the 1988 cohort, the principal determinant of 
mortality on multivariate analysis was best FEV, [increased risk per 10% deficit l-32 (Cl 
1.18-l *47)]. On stratification by quartile of pulmonary function, SMR was lowest and less 
than unity in the fourth quartile of best function, but lowest in the third quartile of actual/best 
PEF. As numbers were small, the confidence intervals in the higher quartiles did include unity; 
e.g. in 1988-93, observed deaths (SMR, Cl) were: 46 (1.8, 1.3-2.5); 24 (1.4, l-O-2.1); 14 (O-79, 
0,43-1.3); 17 (1.2, 0.72-2.0) in the first to fourth quartiles of actual/best PEF. In those aged ~65 
years, the non-significant trend remained after correction for best FEV, k2=6*16, O*l<P<O.2). 
In summary, the actual best/function of those with least symptoms was of the order of 90-95%. 
These subjects may have a relative survival advantage over those in whom the reversible 
component is totally suppressed. This may be absolute if best FEV, is maintained at or above 
100% predicted. 
A comparison of the changing characteristics of ventilated asthmatics over a 
16-yr period 
D. R. GRAHAM, S. T. ATHERTON AND S. KIERNEY 
Whiston Hospital, Prescot, Merseyside, U.K. 
This unit previously reported a retrospective study (1974-83) of ventilated asthmatics (Luksza, Thorax 
1986; 41: 459). This study compares the characteristics and management of these patients with that of 
a subsequent group of ventilated asthmatics (1986-91). 
The patients in the 198691 group had shorter acute attacks with more respiratory arrests; 
more patients were on both oral and inhaled steroids. Ventilation techniques were modified 
in 1986-91 as bronchial lavage was no longer routine, and smaller tidal volumes reduced 
inflation pressures. There was a reduction in mortality with fewer complications in the second 
period. 
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Time period 1974-83 1986-91 
Numbers 
Mean age (years) 
Male:female 
Duration attack 
(mean) ~24 h 
Respiratory arrest 
Oral prednisolone 
Inhaled steroids 
Severity and ventilation 
Mean pulse 
Hypercapnoea 
Complications 
Infection 
Pneumothorax 
Mortality 
34 38 
39.9 (16-72) 38.6 (15-71) 
9:25 12:26 
8.6 4.8 days 
5 patients (15%) 15 patients (40%) 
5 13 
6 16 
7 28 
139 
13 (72%) 
12 (35%) 
6 (18%) 
3 patients 
131 
20 (76%) 
5 (13%) 
2 (5%) 
1 patient 
Is the smaller intrinsic efficacy of salmeterol of functional significance? 
R. W. FOSTER, N. A. ZOUGH AND R. C. SMALL 
Smooth Muscle Pharmacology Research Group, School of Biological Sciences, University of Manchester, U.K. 
Salmeterol (salm) shows a smaller intrinsic efficacy than salbutamol (salb) or isoprenaline (isop) 
(Dougall et al., Br J Pharmacol 1991; 104: 1057). The present authors have investigated whether the 
theoretical functional consequences of partial agonism (greater susceptibility to functional antagonism 
and antagonism towards a fuller agonist) can be demonstrated. 
Airway reactivity to inhaled bronchoconstrictor and bronchodilator drugs has been assessed in six 
healthy adult volunteers (four female) using whole body plethysmography. Established methods 
(Foster et al., Br J Clin Pharmacol 1991; 31: 445) have been used to measure the sensitivity of each 
subject to nebulized methacholine and its local rate of elimination, to produce and maintain with it a 
steady state of 35 or 62.5% reduction in specific airway conductance (SC,,) and also to measure the 
sensitivity and responsiveness to nebulized salb under both conditions. All experiments were performed 
three times and measurements of sG,, were means of five estimates, each based on lo-14 pants. 
Bioassays of salm metered dose inhaler (MDI) vs. isop MD1 were performed using these standardized 
subjects. 
After measurement of baseline sG,, and establishment of one or other of the constricted steady 
states, unit dose of salm (25 pug) or of isop (80 pug) was inhaled in a balanced block design; 30 min later 
(20 min for isop) twice this dose was given (making the cumulative inhaled dose three times the initial 
dose); 30 min later (20 min for isop) a just-maximally effective dose of nebulized salb (1480 pug) was 
inhaled. Throughout, measurements of sG,, were made at 1-min intervals for 5 min every 10 min to 
80 min (60 min for isop). 
No significant log dose-response line slope was obtained in 17% of blocks and different slopes in 
25% of blocks. The low dose of isop was functionally antagonized by greater methacholine constriction 
(65 f 4% to 53 f 4%; P c. O-04) and so to a lesser extent was the low dose of salm (53 f 4% to 41 f 5%; 
P c. O*OS). Compared with isop MDI, salm MD1 showed a log,, relative potency of 0.53 f 0.10 at 35% 
bronchoconstriction and 0.66 f 0.13 at 62.5%; the difference in relative potency was 0.13 f 0.16 
(P c. O-45) between the two amounts of constriction. The response to salb 148Opg was no smaller after 
salm than after isop (repeated measures ANOVA). 
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In conclusion, the method was sensitive to greater functional antagonism, yet salm (partial agonist) 
was no more affected than isop (full agonist) and did not antagonize salb, so no functional consequence 
of the smaller intrinsic efficacy could be detected. 
Neutrophil priming in chronic asthma 
H. NELL, Z. WILLIAMS, J. R. JOUBERT AND I? G. BARDIN 
Internal Medicine, University of Stellenbosch, Cape Town, South Africa 
Neutrophils may be key mediators in the inflammatory response that is characteristic of asthma. The 
authors hypothesized that neutrophils are primed during exacerbations of asthma. A 3-month 
longitudinal study was performed after recruitment of four asthmatic and three normal volunteers. All 
patients were assessed 2-weekly using: twice daily PEF, lo-point symptom score, peripheral blood (PB) 
differential count, PB in vitro neutrophil oxygen radical production (stimulants FMLP, Ca++, PMA) 
and spirometry. Results were displayed graphically to assess the relationship of mPEF to oxygen 
radical production. Measurements were correlated using Spearman rank correlation. In spite of a 
coefficient of variation (CV) >30% in control patients, a significant direct correlation (rz0.7, P<O*O5) 
was demonstrable between mPEF- and FMLP-stimulated neutrophil production of oxygen radicals. 
No other correlations were noted. Although technical constraints limit neutrophil functional assess- 
ments, these results suggest that primed neutrophils are absent peripherally and may be accumulated 
in the lung during episodes of airway obstruction. 
Malignant mesothelioma cells secrete increased amounts of procollagen compared with 
normal mesothelial cells, and are further stimulated by TGF-fi, 
J. S. DAWSON’, S. E. MUTSAERS, M. A. VERSNEL+, G. J. LAURENT* AND R. J. MCANULTY” 
+Centre for Cardiopulmonary Biochemisty and Respiratory Medicine, University College London Medical School, 
London, U.K., and ‘Department of Immunology, Erasmus University, Rotterdam, The Netherlands 
Malignant mesothelioma (MM) is a fibrous tumour of serosal surfaces. While there is a strong 
correlation between MM and previous exposure to asbestos, very little is understood regarding the 
mechanisms of initiation and maintenance of MM growth. Mesotheliomas contain an abundant 
extracellular matrix, consisting predominantly of collagens. They also contain high levels of TGF-P 
isoforms which are potent stimulants of collagen synthesis and deposition. While the role of the 
extracellular matrix (ECM) in MM growth has not been investigated previously, it has been proposed 
that cell-matrix interactions are important determinants of tumour growth and invasiveness. The 
authors hypothesize that collagen, as the major ECM component in MM, is crucial for tumour 
progression, and that blocking collagen production will limit tumour growth. This study has begun to 
investigate this hypothesis by examinating the in vitro rate of procollagen production in three murine 
MM cell lines (AB2, AB22 and AC29) and a normal mesothelial cell line (NM20). Their responsiveness 
to TGF-P, has also been examined at concentrations between 0.4 and 40pM. Hydroxyproline (hyp) 
was measured by reverse-phase high precision liquid chromatography and used as an index of 
procollagen production. The basal rate of procollagen production for MM cells was found to be at 
least double that of NM20 cells (120 f 10 SEM, 13 1 f 2 and 148 f 6 pmol hyp 10 - 6 cells h - ’ for AB2, 
AB22 and AC29 cell lines, respectively, compared with 63 f 6pmol hyp 10 - 6 cells h - ’ for NM20 
cells). NM20 procollagen production was maximally stimulated by 0.4pM TGF-P, (117 f 7% above 
control) which was comparable to the basal rates of procollagen production for the MM cell lines. 
TGF-/?, maximally stimulated procollagen production by MM cells at 40 pM (AB2, 178 f 17%; AB22, 
331 f 7%, and AC29, 53 f 7% above their respective control). In conclusion, MM cells exhibit a higher 
rate of basal procollagen production in comparison to normal mesothelial cells and are further 
stimulated by TGF-P,. Future studies will investigate the effect of blocking collagen production on 
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MM cell growth in vitro and in vivo. This may prove to be a novel therapeutic approach in the 
treatment of this disease. 
This work was supported by the Middlesex Hospital Special Trustees. 
LPS-induced nitric oxide release by freshly isolated rat lung macrophages: inhibition by 
an N-terminal peptide fragment of lipocortin-1 
A. M. KAMAL, T. D. TETLEY, I. R. WITHERDEN AND S. F. SMITH 
Deparfmenf of Medicine, Charing Cross 6s Westminster Medical School, London, U.K. 
Lipocortin-1 (Lc-1) synthesis is upregulated by glucocorticoids, in vitro and in vivo. Induction of 
pulmonary inflammation by lipopolysaccharide (LPS) stimulates inducible nitric oxide synthase 
(iNOS) and bronchoalveolar lavage nitric oxide (NO) levels. This study aimed to monitor NO 
production by alveolar macrophages (AM) in vitro following LPS exposure and to determine whether 
a synthetic peptide fragment of the active N-terminal region of Lc-1, Ac2-26, would mimic the 
anti-inflammatory effect of the glucocorticoid, dexamethasone (DEX), in this model. Rat AM, isolated 
from bronchoalveolar lavage fluid, were plated in to 96-well plates (1.5 X lo5 cells well - ’ in 100 ,ul 
serum-free media) for 3 h. Adherent cells were pre-treated with DEX or Lc-1 peptide for 1 h prior to 
stimulation with graded doses of LPS. Nitrite, the stable breakdown product of NO, was measured 
24 h post-stimulation using the Greiss reaction. The NOS inhibitor, NG-monomethyl L-arginine 
(L-NMMA), caused 84.5% inhibition f 2.27 (mean f SD). Following LPS exposure, there was a dose- 
related increase in nitrite levels; both 30-75pM peptide and l&100 nM DEX inhibited nitrite 
production. Thus LPS stimulation of NO production by freshly isolated AM could be downregulated 
by both DEX and Lc-1 peptide. However, although 100 nM DEX consistently inhibited N 70% of NO 
production, inhibition by 10 nM DEX and both doses of Lc-1 peptide reached a plateau. In conclusion, 
although Lc-1 peptide is required at high levels to downregulate LPS macrophage activation, it may 
have specific anti-inflammatory action, without the side-effects associated with oral glucocorticoids. 
WY tug ml - ‘1 
0.01 0.1 1 10 
,BM nitrite 10 -6 cells 
Inhibition (%) 
30 /&I Ac2-26 
75 pM Ac2-26 
10 nM DEX 
100 nM DEX 
107.65 f 109.17 176.37 f 97.98 191.12 f 12144 237.01 f 148.69 
79.38 f 8.95 67.22 f 12.85 57.37 f 7.24 34.26 f Il.06 
63.56 f 13.82 65.04 f 10.82 60.55 f 10.1 40.96 f 03.63 
83.29 f 10.76 77.66 f 10.53 67.24 f 6.29 54.75 zk 22.78 
88.45 f 0.63 89.36 f 11.75 68.39 f 1.19 70.59 f 4.37 
Data expressed as mean f SD; 12 =2-5 experiments (02 wells experiment - ‘) 
The inflammatory resbonse of the lung following intratracheal instillation of ultrafine 
particles of carbon black 
G. J. PHILLIPS ANb D. G. UPSHALL 
Biology Division, CBD Porfon Down, Salisbuy, U.K. 
Epidemiological studies indicate that increased morbidity and mortality observed during pollution 
episodes is associated with an increase in the mass of airborne particulates (Anderson et al., Thorax 
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1995; 50: 1188). Further, studies implicate that particles of less than 100 nm in diameter, the ultrafine 
fraction, can enter the parenchymal interstitium and initiate an inflammatory reaction. However, little 
data is available as to the time course of this reaction. Thus, in the present study, the inflammatory 
response associated with an intratracheal instillation of ultrafine particulates of carbon black was 
investigated. Male Porton Wistar rats (200 g) were anaesthetized by halothane inhalation and instilled 
with a 5OOpg suspension of carbon black (13 nm diameter) in 100~1 of sterile, non-pyrogenic saline. 
Control animals were instilled with an equivalent volume of saline. All animals were left to recover and 
at 6, 12, 24,48, 72 and 96 h following exposure a bronchoalveolar lavage (BAL) was performed. BAL 
fluid neutrophil numbers were measured as a marker of inflammation and BAL fluid protein was 
measured as a marker of microvascular permeability. 
Results indicate that exposure to ultrafine particles of carbon black initiates pulmonary inflam- 
mation and injury within 12 h of instillation. Although neutrophil numbers remain elevated for up to 
72 h after the initial insult, lung injury as measured by BAL fluid protein returned to control levels by 
24 h. 
Time 
@I 
BAL fluid neutrophils BAL fluid protein 
(lo4 cells ml- ‘) (mg ml- ‘) 
Saline Carbon black Saline Carbon black 
6 0.09 f 0.09 2.34 f 2.60 0.09 f 0.04 0.12 f 0.07 
12 0.27 f 0.30 6.62 f 4.45* 0.08 f 0.04 0.36 f 0.19* 
24 0.04 f 0.05 1.98 f 1.54 0.14 * 0.12 0.07 f o-01 
48 0.08 f 0.06 3.23 I!= 2.01* 0.12 f 0.07 0.10 f o-03 
72 0.05 f 0.06 1.07 f 0.75* 0.16+0.11 0.08 k 0.02 
96 0.03 f 0.06 0.25 f 0.3 1 0.05 f 0.01 0.11 +0.06 
The toxicity of four carbon black samples with Clara cells isolated from mouse 
S. A. M. MURPHY’, F. POOLEY+ AND R. J. RICHARDS” 
*School of Molecular and Medical Biosciences, and ‘School of Engineering, University of Wales, Cardif, UK 
Epidemiologists have associated an increase in mortality and hospital attendance with increases in 
PM10 during pollution episodes, but the biological mechanisms to explain such observations are 
unknown, In the U.K., the composition of PM10 is highly variable, but can contain up to 80% diesel 
ultrafine particles, many of which contain high concentrations of inorganic carbon. This study was 
undertaken to assess the toxicity of four carbon black (CB) samples in order to provide a control 
carbon sample for comparative studies with ultrafine diesel /PM10 particles, with differing surface 
chemistry. Primary isolates of Clara cells from mouse were utilized in toxicity assays as they are known 
to be susceptible to diesel. Five different concentrations (lo-5OOpg) of each of the four CB samples 
suspended in 100~1 of DCCMI were added to a 96well, extra-cellular matrix coated plate. 
Immediately thereafter, pure isolates of the Clara cells were added (lo5 cells in 100~1 DCCMI, 2% 
glutamine, 2% Ultroser G). The cells were then cultured in an atmosphere of sir/5% CO, at 37°C for 
24 h, whereafter they were washed thoroughly. The remaining attached cells were stained for 
NADPH-dependent nitroblue tetrazolium reductase, a marker for functional activity in Clara cells, 
and the number of functional cells compared to control. Toxicity was assessed as the plating efficiency 
of functional cells to the biomatrix. The four CB samples were designated M900, M880, Ml20 and 
R250 and their TD50 values were 50, 54, 177 and 105 PM, respectively. Surprisingly, the least toxic CB 
samples (Ml20 and R250) possessed the greater number of ultrafine particles as assessed by light 
microscopy (LM), M900 and M880 appeared to be comprised mainly of larger particles or particle 
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aggregates. Particle uptake was observed (LM) with all CB samples, but far higher number of particles 
were taken into cells dosed with the CB samples Ml20 and R250. Particles were observed mainly in 
cells with low NADPH-reductase activity, although electron microscopy will be required to confirm 
that these cells are Clara cells, and to identify intracellular particle size, number and aggregation. In 
conclusion, Clara cells in vitro respond differently to similar-sized ultrafine CB samples, which may 
relate to the status of the cell, particle number or surface chemistry. As a result of the studies described, 
Ml20 has been chosen as a control ultrafine for comparative studies with diesel and PM10 samples 
both in vivo and in vitro. 
In situ RT-PCR to identify rhinovirus replication in epithelial cells 
P. J. BATES, G. SANDERSON, S. T. HOLGATE AND S. L. JOHNSTON 
University Medicine, Soufhampfon General Hospital, Soufhampfon, U.K. 
Upper respiratory tract viral infections, or colds, trigger acute exacerbations of asthma. The most 
frequent virus type involved is rhinoviruses (RV), but it is unclear whether these viruses cause an 
inflammatory response in the lung due to infection spreading to the lower airways or as the result of 
an indirect mechanism. To address this, the authors have developed an in situ reverse transcription 
polymerase chain reaction (in situ RT-PCR) for RV that allows sensitive localization of virus within 
specific cells. HeLa cells were infected with a known inoculum of RV-16 in vitro for 18 h, suspended in 
plasma allowed to clot, fixed in 10% formalin overnight and paraffin-embedded. Four-micrometre 
sections on glass microscope slides were pre-treated with a protease to permit selective entry of reagents 
and a DNAse to reduce background signal. Following RT with an antisense primer for RV-RNA, 15 
cycles of PCR consisting of 94°C x 40 s and 55°C x 90 s were performed using specific sense and 
antisense primers. The reaction mixture was sealed over the sections and included 0.5 mM digoxigenin- 
1 I-dUTP that was incorporated into the 380 b.p. product during amplification. The labelled DNA 
retained inside cells was detected by an antibody-based enzymatic colour reaction and visualized by 
light microscopy. The results showed cytoplasmic infection event at levels of inoculum that did not 
subsequently demonstrate significant cytopathogenic effect in HeLa cells. Negative controls were 
RV-infected HeLa cells where the RT enzyme had been omitted, uninfected HeLa cells and HepII cells 
infected with adenovirus-2, all of which showed no signal. In situ RT-PCR appears to be of comparable 
sensitivity to standard PCR techniques for the detection of rhinovirus but has the advantage of 
visualization within the cell. 
Determination of pulmonary surfactant phosphatidylcholine species by electrospray 
mass spectrometry (EMS) 
P. M. HOCKEY*, A. MANDER+ AND A. D. POSTLE+ 
University Departments of *Medicine and ‘Child Health, University of Southampton, U.K. 
Phosphatidylcholine (PC) comprises 80% of pulmonary surfactant phospholipid composition and is the 
fraction predominantly responsible for surface tension activity. Traditionally, phosphatidylcholine 
species have been determined by thin layer chromatography or high precision liquid chromatography; 
techniques which are lengthy and require large volumes of concentrated surfactant recovered 
from bronchoalveolar lavage (BAL) fluid. Recently, the authors have developed and validated an 
EMS technique for the determination of surfactant PC species which is rapid (2 min) and very 
sensitive (<800$ BAL). This advance in methodology has considerable implications for future studies of 
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surfactant abnormalities in a wide range of respiratory disorders, especially when amounts of airway 
sample are limited. 
100 I 
Internal standard 
700 720 740 760 780 800 820 840 
Dale 
Expression of TTF-1 and HNF-3 proteins in guinea pig lung development prior to the 
onset of surfactant apoprotein A (SP-A) gene expression 
H. YuAN”‘+, S. GOWAN’, F. J. KELLY+ AND C. D. BINGLE’ 
“DH Department of Toxicology, St Bartholomew’s and the Royal London Hospifal School of Medicine and Dentistry, 
London, and ‘Cardiovascular Research, The Rayne Institute, St Thomas’ Hospital, London, U.K. 
Thyroid transcription factor-l (TTF-1) and members of the Hepatocyte Nuclear Factor-3 (HNF-3)/ 
forkhead family of protein are critically involved in the regulation of pulmonary epithelial cell 
specific genes including the surfactant apoproteins (SP) and the Clara cell secretory protein gene. 
Members of both of these families have also been directly implicated in the process of tissue 
morphogenesis. To more clearly define the spatial-temporal role that these proteins play in 
pulmonary development, the authors have undertaken to study their expression in the pre-natal 
guinea pig lung. Reverse transcription polymerase chain reaction was performed with total lung 
RNA and degenerate primers designed to amplify a portion of guinea pig TTF-1 and the conserved 
DNA binding domain of HNF-3lforkhead proteins. These clones were then used as probes on 
Northern blots of total lung RNA from different stages of development. Additionally, the 
developmental changes in SP-A gene expression were studied in the same samples using a probe to 
full length guinea pig SP-A. At the earliest time point studied (Day 35, normal gestation=Day 68), 
both TTF-1 and HNF-3/‘orkhead proteins were expressed at levels similar to those seen around the 
time of birth. In contrast, expression of SP-A was not seen until between Days 60 and 65 of 
gestation, suggesting a significant uncoupling of expression of this target gene and its regulators. To 
more clearly identify the sites of expression of TTF-1 within the developing lung, immunohistochem- 
istry with an antibody raised against rat TTF-1 was used. In Day 35 lungs, there was abundant 
staining of the nuclei of cells lining the developing bronchiolar epithelium. As lung development 
progressed, there was a shift of staining into the alveolar regions, although some bronchiolar 
epithelial cells were still TTF-1 positive. The authors are presently extending these studies using in 
situ hybridization to look at the expression of TTF-1 and HNF-3/forkhead proteins in individual cell 
types within the developing guinea pig lung. These findings add to the body of evidence which 
suggest that these proteins play a role in the regulation of genes other than the surfactant 
apoproteins within the developing lung. 
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Lack of involvement of eicosanoids in the secretory response of sheep airway epithelial 
goblet cells to ATP 
M. LETHEM’, K. ZHAO”, E. ADAM+ AND U. SCHUMACHER+ 
“Department of Pharmacy, University of Brighton, and ‘Department of Human Morphology, University of 
Southampton, U.K. 
Respiratory mucus hypersection resulting in airway obstruction, particularly of small airways, is a 
characteristic feature of several respiratory diseases including asthma, chronic bronchitis and cystic 
fibrosis. These conditions are characterized by goblet cell hyperplasia in which goblet cells, which 
secrete the major macromolecular constituents of mucus, mucins, both increase in number and 
appear in distal airways from which they are normally absent. However, due to the presence of 
submucosal glands in the accessible large airways and difficulties in quantifying mucin secretion, the 
regulation of goblet cells is poorly understood. The authors report the development of a lectin-based 
assay for sheep respiratory mucin and its use with airway epithelial explants, in which goblet cells 
are the sole source of mucin. This system has been employed to investigate the suggestion that the 
secretory response of goblet cells to ATP is mediated in part by eicosanoids, in particular by 
prostaglandin E, (PGE,). Histological sections of sheep trachea were screened by lectin histochem- 
istry against a panel of 18 lectins. Several lectins showed specific positive staining of goblet cells and 
one of these (Helix pomatiu agglutinin) was incorporated into a microtitre plate assay with a 
sensitivity of O-25 ng well - ’ of mucin. To measure the secretory activity of goblet cells, airway 
epithelial explants were mounted in Ussing chambers and perfused on both sides with medium. 
After equilibration, samples of mucosal perfusate were collected both during a baseline period and 
while the cells were exposed to ATP, and subsequently analysed for mucin content by lectin-based 
assay. Baseline levels of secretion were 13.1 f 1 a9 ng min - ’ cm - * (n=6); however, bilateral ATP 
(10 - 4M) resulted in a rapid increase in secretion to 654 f 11.9 ng min - ’ cm - 2 (n = 6), after which 
secretory activity returned to near baseline levels over a period of approximately 15 min. The 
identity of the secreted material was confirmed as mucin by CsCl density gradient ultracentrifu- 
gation which indicated that the lectin positive material had a density of 1.38-1.53 g ml - I, similar to 
values reported previously for other mucins. Treatment of the explants with the cycle-oxygenase 
inhibitor, indomethacin (2 x lo6 M, lt=6), or the phospholipase A, inhibitor, quinacrine (3 x lo4 M, 
yt=9), had no effect on the secretory response to ATP, although quinacrine alone resulted in a 
two-fold increase in secretion. Furthermore, PGE, (3 x 10 - 6 M, y1= 6) had no effect on secretory 
activity. These studies indicate that this assay and explant system is capable of monitoring secretory 
responses of sheep airway goblet cells and that the secretory response to ATP is not mediated by 
eicosanoids. 
Bronchoalveolar lavage cells from patients with chronic non-productive cough release 
histamine after challenge with substance P 
P. FORSYTHE+, L. P. A. MCGARVEY*+, L. M. CROSS”, L. G. HEANEY+, J. MACMAHON+ AND 
M. ENNIS 
“Department of Clinical Biochemistry, The Queens University of Belfast, and ‘Department of Respiratory Medicine, 
Belfast City Hospital, U.K. 
Neurogenic inflammation is thought to play an important role in the pathogenesis of inflammatory 
disease such as asthma. In non-asthmatic patients with chronic non-productive cough (CNPC), there 
is preliminary evidence to show increased mast cell and eosinophil numbers in bronchoalveolar lavage 
(BAL) and induced sputum samples, respectively. The authors have demonstrated previously (Cross et 
al., Clin Exp Allergy 1994; 24: 993) that BAL mast cells from atopic asthmatic patients release more 
histamine on challenge with substance P than do those from non-atopic control subjects. The aim of 
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this study was therefore to examine the action of this neuropeptide on cells obtained from patients with 
CNPC. 
BAL (180 ml, right middle lobe) samples were obtained from six non-asthmatic CNPC patients and 
four non-atopic control subjects. All subjects were non-smokers and spirometry was within normal 
limits [PC,, (histamine) >8 mg ml - ‘I. The cells were washed, resuspended in Tyrode’s buffer and 
stimulated with substance P (20 min). Histamine release was measured in supernatants and cell pellets 
using an automated fluorometric assay. Data are presented as percentage histamine release, given as 
means f SEM. 
BAL cells from patients with CNPC released significantly more histamine on challenge with 
substance P than did those from non-atopic control subjects (SP 25 PM, 18.4 f 4.1% vs. 5.2 f 1*6%, 
PcO.05). These data are similar to those found using cells from asthmatic subjects, indicating that in 
CNPC, mast cell reactivity is increased. They are also in keeping with the authors’ findings that there 
is on-going mast cell degranulation in the airways of patients with CNPC, as evidenced by increased 
concentrations of tryptase measured in BAL (McGarvey et al., unpubl.); as is also found in asthmatics. 
Investigation of the role of airway mast cells, including their response to other neuropeptides, and their 
mediators in the pathophysiology of CNPC may therefore aid the further understanding of this 
common and troublesome condition. 
Inflammatory mediators in bronchoalveolar lavage fluid from patients with chronic 
non-productive cough 
L. I? A. MCGARVEY*‘+, l? FORSYTHE*, L. G. HEANEY+, J. MACMAHON+ AND M. ENNIS* 
“Department of Clinical Biochemistry, The Queen’s University of Belfast, and ‘Department of Respiratory Medicine, 
Belfast City Hospital, U.K. 
Cough is a common symptom of asthma, a condition which is associated with elevated inflammatory 
cell numbers and mediator concentrations in bronchoalveolar lavage fluid (BAL). In non-asthmatic 
patients with chronic non-productive cough (CNPC), increased mast cell and eosinophil numbers have 
also been reported in BAL and induced sputum samples, respectively. However, there are no reports 
regarding mediator levels in BAL from patients with CNPC. 
BAL (180 ml, right middle lobe) samples were obtained from 17 CNPC patients (50 f 3.0 years) with 
a median duration of cough of 96 months (range 4-456 months) and seven control subjects. All 
subjects were non-smokers and spirometry was within normal limits. Lavage volume return, differen- 
tial cells counts, tryptase and ECP concentrations were compared in both groups. 
Volume return was significantly less in the CNPC patients (70 f 2 ml vs. 91 f 7 ml, P~0.01). The 
percentage epithelial cells was lower in CNPC patients (6.6 f 0.93% vs. 10.8 f 1*9%, PcO.05); however, 
other cell counts did not differ. Tryptase concentrations were significantly higher in CNPC patients 
(1.97 f 0.09 U 1 - ’ vs. 1.75 f 0.09 U l- ‘, PcO.05). ECP was detected in BAL from five of 15 CNPC 
subjects (measured range 3*56-15.95pg l- ‘) but below the level of detection (2pg l- ‘) in all other 
CNPC and control subjects. 
These data do not support previously reported inflammatory cell recruitment to the airways in 
CNPC. However, elevated tryptase concentrations in BAL from these patients may suggest that mast 
cells are involved in the pathophysiology of chronic cough. Furthermore, raised ECP concentrations 
were found in a subgroup of CNPC patients suggesting ongoing eosinophil activation. However, only 
two of these five subjects had mild non-specific bronchial hyper-responsiveness [PC,, 
(histamine)=4 mg ml - ‘1 and fulfilled the current diagnostic criteria for cough variant asthma. 
Analysis of BAL mediators may allow a more accurate characterization of the underlying pathophysi- 
ology of chronic non-productive cough. 
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Cytokine expression and allergen responsiveness of asthmatic bronchial biopsies 
in culture 
Z. JAFFAR, K. ROBERTS, R. DJUKANOVIC AND S. HOLGATE 
University Medicine, Southampton General Hospital, U.K. 
Asthma is a complex disorder characterized by airway hyper-reactivity and inflammation. The authors 
have developed a bronchial explant model to study cell-cell interactions and the spectrum of cytokines 
produced by the asthmatic lung mucosa. Lung biopsy tissue from nine mild atopic asthmatics and 
seven healthy control subjects were cultured in defined media for 24 h. To detect reactivity to allergen, 
the lung tissue was challenged with dust mite extract Dermatophagoidespteronyssinus (Der p). Maximal 
response of the T cell component of the tissue was induced by stimulation with the T cell mitogen 
phytohaemagglutinin (PHA). Reverse transcription polymerase chain reaction (RT-PCR) analysis and 
ELISA were used to detect cytokine mRNA transcripts and protein production, respectively, by lung 
biopsies and peripheral blood mononuclear cells (PBMCs) in culture. 
Without any overt stimulation, both asthmatic and normal biopsies expressed mRNA for IL-6 and 
IL-8 after culture. In contrast to normal lung, asthmatic biopsies expressed more mRNA and protein 
for IL-5 and IL-13 but less IFN,. Stimulation of biopsies with Der p allergen did not change the 
cytokine profile of normal tissue but augmented the expression of IL-5 in the asthmatic lung. As 
expected, PHA stimulation of the bronchial tissue from both study groups induced the expression of 
most cytokines including mRNA for IL-2 IL-4 and IL-9. PBMCs from asthmatics produced higher 
levels of IL-5 and IL-13 proteins compared to normals but only after stimulation with PHA. In 
addition, unlike lung biopsies, the production of IFN, from PHA-stimulated PBMCs was not 
significantly different between the two study groups. These results demonstrate that clear differences 
are evident in the spectrum of cytokines expressed by atopic asthmatic lung compared to normal tissue. 
These effects appear to be specific to the lung since the data differ from that observed with PBMCs 
from the same individuals. 
Increased expression of intercellular adhesion molecule-l (ICAM-1) on sputum T-cells 
in asthma 
L. STANCIU, R. LOUIS, J. SHUTE, S. BIAGI, F. MARELLI AND R. DJUKANOVIC 
University Medicine, Southampton, U.K. 
Intercellular adhesion molecule 1 (ICAM-1) is both an adhesion molecule and a marker of T-cell 
activation. Using flow cytometry, the authors have investigated the expression of surface ICAM- on 
T-cells in the sputum and blood in atopic asthmatics (n= 14) and non-atopic, normal (n= 12) subjects. 
Sputum was induced by hypertonic saline, homogenized with dithioerythritol and, following centrifuga- 
tion, the cells incubated with antibodies against CD3, CD4, CD8, HLA-DR, interleukin-2 (IL-2R, CD25) 
conjugated with either FITC, PE or PerCP. T-cell subsets were determined by Boolean gate analysis. In 
addition, soluble ICAM- (sICAM-1) was determined in the sputum supernatants using ELISA. 
There were no differences between asthmatics and normals in total T-cells, T-cell subsets or T-cells 
bearing IL-2R, HLA-DR or ICAM- 1 in blood. The percentage of ICAM- + , CD25 + and HLA-DR + 
CD3+ T-cells were increased in the sputum as compared with blood in both normal and asthmatic 
subjects. Comparison of sputum between the two groups showed increased numbers of CD3 + CD4 + 
T-cells in asthmatics and a two-fold increase in CD3+ICAM-l+ cells (median 46 vs. 21). This was 
associated with increased levels of sICAM-1 in the sputum of asthmatics. 
This study adds further evidence for upregulation of ICAM- in asthma which may predispose 
patients to infections with rhinoviruses which use ICAM- as a receptor. The increased number of 
ICAM- + T cells in the airways may be explained by increased transmigration of ICAM- activated 
cells from blood. Alternatively, this could result from local activation by inflammatory mediators 
including cytokines (such as TNF), ECP, tryptase or direct upregulation by allergen or viruses. 
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Mast cell tryptase can induce histamine release from human mast cells 
S. HE, M. GACA AND A. F. WALLS 
Immunopharmacology Group, Southampton General Hospital, U.K. 
Tryptase, the major secretory product of human mast cells, is released in large quantities into the 
airways in bronchial asthma. The potential of tryptase and inhibitors of tryptase to modulate the 
activation of lung, tonsil and skin mast cells has been investigated. Tryptase purified from human lung 
tissue induced a dose-dependent release of histamine from dispersed cells. The reaction seemed to 
require an intact catalytic site, being inhibited by heat treating the enzyme or by adding the protease 
inhibitors APC 366 or leupeptin, or the substrate BAPNA. Tryptase-induced histamine release took 
some 6 min to reach completion, required the presence of exogenous calcium and magnesium, and on 
the basis of inhibition by antimycin A and 2-deoxy-D-glucose would appear to be non-cytotoxic. The 
tryptase inhibitor APC 366 significantly inhibited histamine release induced by anti-IgE or calcium 
ionophore, with up to 50% inhibition being observed at a concentration of 100~~. IgE-dependent 
histamine release was inhibited also by leupeptin and BAPNA. The secretion of tryptase from mast 
cells may provide an amplification mechanism by triggering further mast cell degranulation. Inhibitors 
of tryptase may prove valuable as mast cell stabilizing agents in asthma and other allergic conditions. 
Mast cell tryptase stimulates IL-8 release from human endothelial cells 
S. J. COMPTON, J. A. CAIRNS, S. T. HOLGATE AND A. F. WALLS 
Immunopharmacology Group, Southampton General Hospital, U.K. 
Tryptase, a tetrameric serin protease, is the major product of the human mast cell. Mast cells are 
frequently located in the vicinity of small blood vessels, and their activation is likely to result in 
endothelial cells being exposed to high concentrations of tryptase. The authors have isolated tryptase 
from human lung tissue and have investigated its potential pro-inflammatory actions on human 
umbilical vein endothelial cells (HUVEC). Incubation of tryptase with HUVEC stimulated an increase 
in 3H-thymidine incorporation and a dose-dependent release of interleukin-8 (IL-8) as assessed by 
ELISA. Maximal expression of IL-8 (2*5-fold greater than controls) was observed with 100 mU ml - ’ 
tryptase. An increase in IL-8 was apparent as early as 4 h and reached maximal expression at 24 h. The 
release of granulocyte-macrophage colony stimulating factor (GM-CSF) was not affected by tryptase. 
Pre-incubation of tryptase with the protease inhibitor leupeptin or heat inactivation of the enzyme 
significantly reduced IL-8 release and thymidine incorporation indicating dependence on an active 
catalytic site. These findings are consistent with tryptase having a role in the recruitment of 
inflammatory cells in asthma and other allergic diseases. 
Financial support from the Medical Research Council is gratefully acknowledged. 
Rhinovirus infection induces IL-8 promoter activity in a human bronchoalveolar cell line 
D. DUMITRASCU*, G. SANDERSON’, N. MUKAIDA+, K. MATSUSHIMA+, S. T. HOLGATE* AND 
S. L. JOHNSTON” 
“University Medicine, Southampton General Hospital, and ‘Department of Pharmacology, Cancer Research Institute, 
Kanazawa University, ]apan 
Interleukin-8 (IL-8) is a chemo-attractant for neutrophils and eosinophils, inflammatory cells involved 
in the pathogenesis of viral infection and asthma. Rhinoviruses (RV) are associated with the majority 
of asthma exacerbations in children and adults. In vitro studies confirm that the RV increases IL-8 
protein and mRNA in pulmonary epithelial cells, but the mechanisms of this induction are not known. 
The authors’ aim was to determine whether RV infection increases IL-8 promoter activity. A series of 
S’deletion plasmids containing the human IL-8 promoter ( - 1481 to +44 bp) linked to the coding 
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region of the chloramphenicol acetyltransferase (CAT) gene were used to transiently transfect a human 
alveolar type II cell line (A549). Twenty-four hours after transfection, cells were stimulated with RV9 
or control media, and cells were harvested for CAT assay. CAT activity (acetylation of 14C- 
chloramphenicol) was measured in 2OOpg of each cell lysate by thin layer chromatography. Time 
course studies from 24 to 120 h following RV stimulation of the - 1481 bp plasmid (full length 
promoter) showed that CAT protein inducibility was highest at 2448 h after stimulation, but remained 
elevated up to 120 h. The activity of the deletion plasmids was assessed at 24 h following stimulation 
and it was found that the proximal - 252 bp of the IL-8 promoter yielded high inducibility of CAT 
activity by RV9, whereas further deletion failed to permit inducibility. CAT assay revealed that RV 
infection of A549 cells increases IL-8 promoter activity, and that the crucial &elements required for 
IL-8 promoter activity stimulated by RV9 are situated in the proximal 252 bp of the IL-8 promoter. 
Pulmonary T-cell responses in mice expressing a transgenic T-cell receptor specific for 
ovalbumin 
D. RICH, S.-C. LEE, Z. JAFFAR, S. H0LGATE AND K. ROBERTS 
University Medicine, Southampton General Hospital, U.K. 
A major problem encountered when studying T-cell responses in viva is that antigen reactive cells in the 
lung are difficult to distinguish from non-specific T-cells recruited to inflammatory sites. To overcome 
this problem, the authors have used the DO. 11 .lO transgenic mouse which express a T-cell receptor 
(TCR) specific for ovalbumin (ova) peptide presented by the I-Ad class II molecule. Recently, the 
transgenic TCR has been backcrossed onto a BALB/c background (having a H-2d haplotype). 
Following enzymatic disassociation of the lung tissue of transgenic mice, FACS analysis revealed 
that 19.7% of cells were CD4+ T-cells and 7.4% were CD8+ T-cells. In the spleen, 22.8% of cells were 
CD4+ T-cells and 5.4% were CD8 + T-cells. The preponderance of CD4+ T-cells (with few CD8+ 
cells) is a likely consequence of the DO.1 1.10 TCR being specific for antigen presented by MHC class 
II molecules. Reverse transcription polymerase chain reaction (RT-PCR) showed that lymph node and 
mononuclear cells from the lungs of naive mice and mice immunized with ova (using aluminium 
hydroxide as an adjuvant) express IL-4, IL-5, IFN-7 and TNF-a after culture with whole ova in vitro. 
IL-2 protein was detected in the culture supernatants from both naive and immunized DO.1 1.10 cells, 
whereas IFN-)I was detected only in culture supernatants from naive mice. 
To monitor the T-cell response to antigen entering the airways, DO.1 1.10 mice were intra-nasally 
challenged using aerosols of whole ova (2% ovalbumin solution for 20 min day - ’ for 2 days). The 
production of cytokines was determined using RT-PCR. This revealed that the lung tissue from mice 
intra-nasally challenged with ova expressed mRNA for IFN-1/ and TNF-a but not IL-4 or IL-5. In 
contrast, the authors failed to detect any of these cytokines in lungs obtained from animals that were 
not intra-nasally challenged. Mononuclear cell isolated from challenged lungs when restimulated in 
vitro with ova, had greater proliferative responses than lung cells from naive mice (51 966 CPM vs. 
35 655 CPM). These data demonstrate that the intra-nasal challenge of TCR transgenic mice provides 
a means to study airway T-cell responses to antigen. 
Expression of CD44 variant isoforms on bronchial epithelial cells correlates with 
changes in cell phenotype in vivo and in vitro 
J. E. BAKER, H.-S. LEIR, P. M. LACKIE AND S. T. HOLGATE 
University Medicine, Southampton General Hospital, U.K. 
The adhesion molecule CD44 is expressed predominantly on basal cells in the human bronchial 
epithelium, and CD44 expression is increased in asthma (Lackie et al., AJRCMB 1997; in press). 
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Variant isoforms of CD44 (85-300 kDa) are generated by alternative splicing leading to the insertion 
of additional extracellular peptide sequences. In this study, immunoreactivity for total CD44 
(CD44s- mAb’s Hermes-3 and 25.32) and isoforms containing CD44v9 (mAb 11.24) CD44v6 (mAb 
11.9) and CD44v4 (mAb 11.10) have been compared. 
In tissue, CD44s and CD44v9 were seen on basal, but not columnar, epithelial cells. Weak 
CD44v6 immunoreactivity was found infrequently in the bronchus, while CD44v4 immunoreactivity 
was absent. A distinct population of basal cells expressed CD44, and immunoreactivity was locally 
increased in areas of epithelial damage. By FACS and immunocytochemistry of primary bronchial 
epithelial cells and the bronchial epithelial-derived cell lines H292 and 16HBE140 -, standard and 
variant isoforms (CD44v9) were found on all cells. The authors suggest that this correlates with a 
change in phenotype closer to that of basal cells in vivo. Although absent in airway epithelial cells, 
CD44v4 and CD44v6 were detected on a high proportion of cells in culture. Preliminary data 
indicate that treatment of cultured cells with IFNy and TNFa showed differential regulation of 
CD44v6 (reduced) and CD44v9 (upregulated). Such differential regulation by soluble mediators 
could account for the altered expression seen in vitro. CD44s and CD44v9 were significantly 
decreased on cells cultured at high density (2.6 x lo4 cells cm - 2, compared to cells at low density 
(0.6 x lo4 cells cme2 ). Studies are in progress to identify the function(s) of CD44 in bronchial 
epithelium. 
ICAM-I localization and modulation in bronchial epithelium and bronchial 
epithelial-derived cell lines 
H.-S. LEIR”, I?. M. LACKIE”, A. TRIFILIEFF+, A. COLLINSON” AND S. T. HOLGATE” 
*University Medicine, Southampton General Hospital, U.K., and ‘Ciba Geigy AG, Basal, Switzerland 
The adhesion molecule ICAM- is expressed on bronchial epithelial cells during inflammation, and 
expression is increased in asthma (Wegner et al., Science 1990; 47: 456). While ICAM- on endothelium 
is important for the adhesion and extravasation of circulating cells, its role in epithelium is less clear. 
ICAM- is the cell surface binding site for the major group of human rhino viruses which have been 
implicated in episodes of wheezing in asthmatics. To understand the role of ICAM- in normal 
epithelium and in disease, it is necessary to understand the subcellular pattern of expression in 
epithelium (i.e. apical/basolateral polarity) and its control. 
Using confocal and electron microscopy with immunostaining, the authors’ preliminary results 
indicate that ICAM- is only weakly expressed in normal epithelium in vivo. After treatment 
with TNFa and IFNy ex vivo, ICAM- was primarily expressed basally in the epithelium. 
ICAM- expression on the cells lines H292, 16HBE 140 -, 9HTE and BEAS-2B has been 
studied using flow cytometry and immunocytochemistry. The effect of IFNy and TNFa alone 
and in combination was examined. By flow cytometry, H292 cells showed a median ICAM- 
expression of 14 (arbitrary units) which is increased by treatment to 35 (100 U ml - i TNFa), 172 
(100 U ml- ’ IFNy) and 400 (TNFa and IFNy). These trends are consistent between cell lines, 
although the level of ICAM- varies. To examine ICAM- expression in a confluent polarized 
cell line with tight junctions between cells, the cell line 16HBE 140 - was used. These cells were 
grown on polyethylene terephthalate permeable membranes (3pm pore size) and electrical 
resistance was monitored using a conductivity meter to indicate epithelial integrity and the 
formation of functional tight junctions. In polarized 16HBE 140 - 2 cells, immunostaining was 
seen on both the apical and basolateral membrane domains, in contrast to results for tissue 
samples. Further studies are in progress to examine the basis of the differences in expression 
in vitro as compared to in vivo, and to investigate how ICAM- levels can be downregulated 
in vitro. 
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Mast cell tryptase stimulates the proliferation of human airway smooth muscle cells 
H. THABREW, J. A. CAIRNS AND A. F. WALLS 
Immunopharmacology Group, Southampton General Hospital, U.K. 
Increased numbers of smooth muscle cells and a thickened airway wall are characteristic features of 
bronchial asthma. Other prominent features are chronic inflammation of the airways and constant 
degranulation of mast cells. The authors have investigated the potential of the major secretory product 
of the mast cell, the serine protease, tryptase, to act as a growth factor for human airways smooth 
muscle cells. The incubation of primary cultures of smooth muscle cells from human lung with purified 
preparations of lung tryptase was found to increase the incorporation of [3H]-thymidine in a 
dose-dependent manner. Consistent with this was the observation of increased immunocytochemical 
staining for proliferating cell nuclear antigen (PCNA). At 30 mU ml - 1 tryptase, a concentration likely 
to be achieved in the asthmatic airways, there was a maximum increase in thymidine incorporation of 
120% over that for serum-free control cultures. The reaction was inhibited using the protease inhibitors 
leupeptin and benzamidine hydrochloride, and by heat treating the enzyme, indicating dependence on 
an intact catalytic site. The degree of cell proliferation stimulated by tryptase was comparable to that 
obtained with other established growth factors for smooth muscle cells, including 10% serum and 
platelet derived growth factor (PDGF), but certain other serine proteases tested, including trypsin and 
elastase, were without effect. Histamine was itself a growth factor for smooth muscle cells (although 
less potent than tryptase) and when added to cells with tryptase, there was an additive effect. Heparin, 
another pre-formed mast cell product, appeared to have a dual role, inhibiting cell growth directly but 
stabilizing the activity of tryptase. Mast cell tryptase may have a role in inducing hyperplasia of airway 
smooth muscle cells in bronchial asthma. 
Isolation of human peripheral blood dendritic cells for functional studies using high 
gradient immunomagnetic sorting 
J. A. HARTLEY, S. T. HOLGATE AND A. E. SEMPER 
University Medicine, Southampton General Hospital, U.K. 
Pulmonary dendritic cells (DCs) are present at low abundance which precludes their isolation for 
functional studies. Since pulmonary DCs are derived from immature DCs recruited from the blood, the 
authors isolated peripheral blood DCs from normal and asthmatic subjects to determine the role of 
DCs in the initiation and maintenance of allergic inflammatory reactions. Peripheral blood DCs 
comprise less than 1% of total leukocytes. In the absence of specific surface markers for immature DCs, 
existing techniques for DC purification have relied upon the sequential depletion of the major 
contaminating cell types based on their physical characteristics, or using immunoseparation. In this 
study, two methods have been compared for the purification of DCs by either negative or positive 
selection using high gradient immunomagnetic separation. 
Negative selection of DCs was performed on peripheral blood mononuclear cells (PBMCs) depleted 
of monocytes by plastic adherence. Non-adherent cells were incubated with a cocktail of antibodies 
against CD3, CD14, CD16, CD20 and CD56, followed by goat anti-mouse immunomagnetic beads 
(Miltenyi). Magnetically labelled contaminating cells were removed using a high gradient magnet 
(MACS, Miltenyi). Positive selection of DCs was achieved using a DC isolation kit (Miltenyi), in which 
PBMCs are incubated with hapten-conjugated microbeads against CD3, CD 11 b & CD 16, followed by 
anti-hapten microbeads leaving negatively selected B-cells and DCs. From these, DCs are positively 
selected using anti-CD4 microbeads. For both methods, cell viability, yield and purity were assessed by 
flow cytometry. 
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Negative selection yielded DCs which were 20-25% pure (n=7). Average yields were 3.98 x lo6 cells 
of which 0.89 x lo6 were DCs (50% of expected DCs). Major contaminants were T-cells, NK cells and 
some monocytes. Positive selection using the DC isolation kit resulted in a purity of 5575% (n = 7), and 
on one occasion 95%. Yields were on average 0.34 x lo6 (20% expected DCs) with 95% viability. Major 
contaminants were B-cells with some T-cells, NK cells and a few monocytes. There was also a 
population of cells which have not been identified. 
DCs isolated using the DC isolation kit are of superior purity to those isolated by negative selection 
alone. However, yields using the kit are lower. This may be due to the antibodies used, notably CD1 lb 
which has been reported to be present on a subpopulation of DCs and CD4, which is probably not 
present on all DCs. Thus, the DCs isolated using the kit comprise a subpopulation of peripheral blood 
DCs. They are, however, clear of some significant contaminants, notably monocytes, which will be of 
importance for future studies of antigen presenting cells function. 
Calprotectin, a urinary marker of disease activity in severe asthma 
J. SHUTE*, M. FAGERHOL+, J. PARMAR”, S. HOLGATE* AND P. HOWARTH” 
“University Medicine, Southampton General Hospital, U.K., and ‘Ulleval Hospital, Oslo, Norway 
Calprotection is a member of the S-100 family of calcium-binding proteins. It is predominantly 
expressed by neutrophils and is a plasma marker of inflammation in cystic fibrosis. This study 
measured calprotectin in bronchial lavage fluid (BLF) and urine samples in patients with severe asthma 
and, in view of the known affinity of calprotectin for zinc, it was investigated whether calprotectin is 
an inhibitor of the zinc-dependent matrix metalloprotease MMP-9. 
Calprotectin was measured by specific sandwich ELISA and inhibition of MMP activity by 
zymography. Eosinophils were purified (99.5%) by immunomagnetic separation of a mixed granulocyte 
preparation from normal blood, and lysed in PBS/l% Triton X-100. 
Calprotectin levels in BLF from normal subjects (207.9 f 19-O ng ml - ‘) and patients with severe 
asthma (209.5 f 27.5 ng ml- ‘) were not significantly different. In a group (n=22, 7 M) of patients 
admitted with acute severe asthma, calprotectin levels in urine samples collected the morning following 
admission were significantly (P<O*O2) higher (333 f 20 ng ml - ‘) compared to normal samples 
(221&33ngml-‘, n= 15, 7 M). Measurements in normal urine demonstrated significantly (P<O*OOl) 
higher levels in females compared to males. Recently, the authors found that normal peripheral 
eosinophils express MMP-9, and the authors now report the presence of calprotectin in normal 
eosinophils. Purified calprotectin inhibited MMP-9 activity in gelatin substrate gels with an IC,, of 
6Opg ml- ‘. 
Therefore, the authors propose that calprotectin is released during inflammatory cell recruitment in 
acute exacerbation of asthma and inhibits zinc-dependent matrix metalloprotease activity. 
Macromolecular forms of chemokines in the airways in asthma and cystic fibrosis 
B. PERKS, C. H. HILLABY, J. 0. WARNER AND J. K. SHUTE 
Departments of Medicine and Child Health, Southampton General Hospital, U.K. 
Interleukin-8 (IL-8), a potent neutrophil chemo-attractant, is known to bind to a number of 
macromolecules including heparin, immunoglobulins and qmacroglobulin. It is not detected as the 
free cytokine in the circulation or airways of normal individuals. However, free IL-8 is found in the 
sputum of individuals with cystic fibrosis (CF), a disease characterized by neutrophil infiltration, but 
not in sputum induced in individuals with mild to moderate asthma. Using sputum, the authors 
have now begun to characterize the complexed forms of IL-8. 
DTT-treated (5mM) sputa were separated by heparin affinity chromatography and fractions were 
assayed for neutrophil chemotaxis, in micro-Boyden chambers, and free IL-8 concentration, by 
ELISA. The non-heparin binding neutrophil chemotactic fractions were separated by gel filtration and 
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assayed by the immunoblot technique for IL-8, ENA-78, GRO-a, NAP-2, a,-macroglobulin and 
IgA. 
Heparin affinity separation resulted in a IO-fold increase in the total amount of neutrophil 
chemotactic activity (NCA) detected in all sputa. In CF, free IL-8 accounted for approximately 20% of 
this activity and 55% was attributed to the non-heparin binding fractions. In mild asthma, free IL-8 
was not detected and most NCA was detected in the non-heparin binding fractions. The non-heparin 
binding fractions revealed abundant IL-8 complexed with both IgA and a,-macroglobulin. IL-8 
containing fractions with NCA were found in the molecular weight range 172 000 - 1.4 x 106. NAP-2, 
ENA- and GRO-a exhibited similar profiles. 
Previously, the authors have shown that a,-macroglobulin enhances and heparin inhibits the 
binding of IL-8 to neutrophils in vitro (Ramdin et al., Respir Med 1997; A.25). Therefore, this study 
indicates that complexation of IL-8 and other chemokines with macromolecules may determine the 
localization and bioavailability of the cytokines, suggesting mechanisms by which the inflammatory 
processes are regulated in asthma and cystic fibrosis. 
Epithelial lining fluid antioxidant status during acute rejection of transplanted lungs 
A. WILLIAMS+, G. RIISE+ AND F. J. KELLY* 
*Cardiovascular Research, The Rayne Institute, St Thomas’ Hospital, London, U.K., and ‘Department of Respiratory 
Medicine and Allergology, Sahlgrenska University Hospital, Gofhenburg, Sweden 
Lung transplantation is now an acceptable therapy for many end-stage pulmonary diseases. Organ 
rejection is still a relatively common problem and often the cause remains obscure. This study 
examined whether lung epithelial lining fluid antioxidant status could be used as an early marker of 
rejection. Nineteen individuals, mean age 41.3 f 10.9 years, underwent a transplant (single lung, 
double lung or combined heart and lung). Bronchoalveolar lavage and blood samples were taken 2 
weeks, 1, 2, 3, 6 and 12 months post-transplant, at which time subjects were also assessed for evidence 
of tissue rejection. Bronchoalveolar lavage fluid (BALF) and serum were analysed for a range of 
antioxidants including a-tocopherol (a-tot), ascorbic acid (AH,), uric acid (UA), reduced thiols, 
reduced (GSH) and oxidized (GSSG) glutathione. BALF protein (an indicator of lung injury) and 
BALF and serum malondialdehyde (MDA; marker of oxidative stress) concentrations were also 
determined. In this preliminary analysis, results are presented for the 2-week post-transplant samples. 
Patients were divided into those who showed no initial rejection (Group A, n= 12) and those who 
showed acute rejection (Group B, n=7). Results were analysed using the Mann Whitney u-test for 
non-parametric data. 
BALF Serum 
Group A Group B Group A Group B 
AH, @mol I- ‘) 0.14 (0.10, 0.11) 0.12 (0.10, 0.13) 2.37 (0.34, 6.15) 4.80 (1.11, 8.55) 
UA &mol 1 - ‘) 3.93 (1.88, 12.70) 6.84 (3.67, 8.58) 78.7 (67.5, 100.1) 84.5 (76.6, 167.4) 
Thiols @mol 1 - ‘) 3.45 (2.1, 11.63) 2.85 (1.76, 4.19) 219 (136.5, 289.3) 243 (149.1, 291) 
MDA (nmol 1 - ‘) 5.01 (5, 17.7) IO.33 (5.21, 23) 1229.3 (641.1, 2603.2) 770.4 (610.4, 1291.9) 
a-tot @mol 1 - ‘) nd nd 23.6 (15.5, 27.9) 20.9 (16.5, 28.8) 
GSH Curno - ‘) 0.54 (0.23, 0.91) 0.84 (0.47, 1.17) na na 
Data are presented as median (25 percentile, 75 percentile). na, not assayed; nd, none detected. Considerable 
inter-individual variability for each parameter was found and no statistical differences were seen between the two 
groups for any of the indices measured. These preliminary results suggest that antioxidant status is not an 
important factor in determining acute lung rejection in the period immediately following transplantation. 
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Washout of uric acid during serial nasal lavage is masked in normal subjects exposed 
to hydrogen fluoride by its increased movement into the upper airways 
C. DUNSTER’, K. LUND+, M. REFSNES+, P. SOSTRAND’, J. KONGERUD+, J. BOE” AND 
F. J. KELLY’ 
“The Rayne Institute, St Thomas’ Hospital, London, U.K., ‘Department of Thoracic Medicine, Rikshospitalet, *National 
Institute of Public Health, and ‘National Institute of Occupational Health, Norway 
Exposure to fluorides have been associated with asthmatic symptoms amongst aluminium potroom 
workers. It is likely that hydrogen fluoride (HF) reacts with uric acid (UA), the primary antioxidant 
present in upper respiratory tract lining fluid. The objective of this study was to examine the depletion 
and repletion kinetics of UA in the upper airways in subjects exposed to HF. Ten healthy subjects were 
exposed to HF (3.3-3.9 mg m- 3, or air for 1 h on separate occasions. The two exposures were 
separated by at least 3 weeks. Nasal lavage (NAL) was performed before (to), immediately following 
(t60) and 1.5 h post-exposure (t150). The recovered NAL fluid was analysed for UA and total protein, 
The data, expressed as medians (interquartile ranges), were analysed by Freidman Repeated Measures 
ANOVA. 
Air HF 
Total protein to 0.42 (0.26,0.83) 0.40 (0.35,0.57) 
(mg ml - ‘) t60 0.31 (0.19,0*42) 0.38 (0.28,0.62) 
t150 0.27 (0.16,0.37)* 044 (0~3,055) 
Uric acid to 25.8 (19.6,30.5) 23.4 (18.7,29.3) 
(PM) t60 18.8 (16.0,22.1) 21.0 (16.9,31.8) 
t150 18.6 (14.5,19.5) 26.2 (14.1,31.1) 
*Denotes a difference (PcO.05) from to. 
Serial nasal lavage resulted in washout of both protein and UA from the upper airways, as seen 
during air exposure. During HF exposure, this washout effect was not seen, indicating increased 
movement of these moieties into this compartment. The increase in protein in NAL fluid is indicative 
of increased microvascular permeability of the nasal membranes due to damage to the epithelial layer 
following exposure to HF. Repletion of UA in NAL fluid following HF may be due to both increased 
UA movement from the vasculature as well as increased UA secretion from nasal epithelial cells, 
implying a compensatory mechanism designed to avoid further injury. 
SV4O immortalization of human lung small airway epithelial cells 
S. E. CHANG*, C. BINGLE’, C. POWELL*, I. WITHERDEN+, T. TETLEY+, D. LI* AND P. JEFFERY* 
“DH Toxicology, Queen May 6 Westfield College, ‘Department of Medicine, Charing Cross 0 Westminster Medical 
School, and *Lung Pathology, Royal Brompton Hospital, London, U.K. 
Although there are reports of in vitro immortalized epithelial lines derived from the larger bronchi or 
upper airways of human lung, there appear to be no such lines from the small airways. The authors’ 
intention is to establish a panel of in vitro immortalized small airway cell lines which show a Clara and 
type II cell phenotype. Primary cultures derived from tissue re-sections of peripheral lung are 
dominated by two different epithelial colony phenotypes which can be passaged once or twice only. 
SV40 DNA transfection of the primary cultures has allowed the isolation of at least five SV40- 
transformed cell strains showing an extended lifespan in vitro. Some of these cell strains die in crisis but 
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others may be progenitors of immortal lines. The simple epithelial nature of the transformed cells is 
confirmed by immunocytochemistry. Keratins 7, 8, 18 and 19 are usually observed. Experiments are in 
progress to determine whether the transformed cells have a Clara or type II cell phenotype, and 
whether they show increased xenobiotic activity (cytochrome P45Os and phase 2 conjugating enzymes) 
in the presence of chemical inducers (in collaboration with Val Baker, Unilever). SEC is funded by 
Unilever Plc. 
Modulation of neurogenic mucus secretion in ferret trachea in vifro by endogenous 
vasoactive intestinal peptide 
Y.-C. LIU, A. M. KHAWAJA AND D. F. ROGERS 
Thoracic Medicine, National Heat-f 0 Lung Insfifufe, Imperial College, London, U.K. 
Vasoactive intestinal peptide (VIP) is co-localized with acetylcholine and may regulate cholinergic 
neurotransmission in airway smooth muscle. The authors investigated the effects on neurogenic mucus 
secretion in ferret trachea in vitro by using exogenous VIP, and a specific VIP antiserum (VIP-Ab). 
Ferret tracheal segments were mounted in Ussing chambers and newly synthesized mucins labelled 
with 35S0,. To investigate cholinergic nerve-induced secretion, tissue was pre-incubated with pro- 
pranolol and phentolamine (both at 10pM) to eliminate adrenergic neural influences, and CP-99,994 
(3 PM) to eliminate tachykininergic involvement. Atropine (10 FM) was used in certain experiments to 
eliminate the remaining cholinergic effects. Tissues were electrically stimulated at 50 V, 0.5 ms for 
5 min at either 2.5 Hz (threshold) or 10 Hz (near maximal). Data are mean f SEM, representing the 
percentage of increased mucus secretion compared with previous collection. 
Exogenous VIP dose-dependently increased mucus secretion, with an E& of 0.7 PM and a maximal 
increase of 57 f 6% at 10pM (P<O*Ol, n=5). VIP-Ab (1:500 dilution) inhibited secretion induced at all 
concentrations of VIP examined, with a maximal inhibition of 66% at 1 FM VIP. VIP-Ab did not 
inhibit acetylcholine (ACh)-induced secretion. VIP-induced secretion was not inhibited by control 
serum. Cholinergic neural secretion was potentiated by 209% by VIP-AB at 2.5 Hz stimulation 
(P<O*O5, 1z=7), but not at 10 Hz (26% potentiation; ns, n=6). Exogenous VIP (0.01 or 0.1 ,LLM) 
significantly suppressed cholinergic mucus release at 2.5 Hz by a maximum of 99% (n=9), and at 10 Hz 
by a maximum of 85% (n=4). VIP did not inhibit ACh-induced secretion (in fact, the response was 
additive). After elimination of adrenergic, tachykininergic and cholinergic neural influences, neuro- 
genie mucus secretion was increased by 28 f 7% at 10 Hz stimulation but not at 2.5 Hz. VIP-Ab 
inhibited the 10 Hz response by 89% (n=8, P<O*O5). 
It is concluded that exogenous VIP increases mucus secretion, as does high-frequency ‘VIP-ergic’ 
nerve stimulation alone. In contrast, endogenous VIP regulates the magnitude of cholinergic neural 
mucus secretion, probably via a pre-junctional mechanism. 
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